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INTRODUCTION 
COUMARIN 
 Natural, synthetic and semisynthetic heterocyclic compounds play an 
important role in drug discovery and chemical biology. The heterocycles are 
mainly of the classes of alkaloids, flavones, isoflavones, chromans, chromones, 
coumarins and chromenes. Synthetic compounds of these classes show different 
biological activity. It has been established that oxygen-containing heterocyclic 
compounds play an important role in designing new class of structural entities for 
medicinal applications [1].  
 Among oxygen heterocyclic compounds, coumarin (2H-chromen-2-one or 
2H-1-benzopyran-2-one) (1) and its derivatives are significant because of their 
wide spectrum of biological activities. 
                            
                                                  
O O
(1)
1
2
3
4
5
6
7
8
9
10
 
  Coumarins owe their class name to ’coumarou’, the vernacular name of the 
tonka bean, from which coumarin itself was isolated in 1820[2]. Coumarins 
comprise a very large class of compounds found throughout the plant kingdom. 
They are found at high levels in some essential oils, particularly cinnamon bark oil 
(7,000 ppm), cassia leaf oil (up to 87,300 ppm) and lavender oil. Coumarin is also 
found in fruits (e.g. bilberry, cloudberry), green tea and other foods such as 
chicory. Most of the coumarins occur in higher plants, with the richest sources 
being Rutaceae and Umbelliferone[4]. They belong to the family of lactones 
having 1-benzopyran-2-one system that can be isolated from plants as well as can 
be synthesized in the laboratory. Coumarin is a crystalline white powder with a 
hay-like, sweet aromatic creamy odor with certain nutty shadings, much used in 
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synthetic form as a fragrance chemical for perfumes and for fragranced soaps and 
detergents. 
 Coumarin is a versatile pharmacophore which exhibits a wide variety of 
biological activities like antibacterial and antimicrobial. Coumarins occupy a 
special role in nature. They belongs to the flavonoid class of plant secondary 
metabolite, which exhibit a variety of biological activities, associated with low 
toxicity and have achieved considerable interest due to their beneficial potential 
effects on human health[5]. Coumarin derivatives have been reported for their 
anticoagulant[6], anti-inflammatory[7], antimicrobial[8], anti HIV[9], antioxidant[10], 
antiallergic, anticancer[11] and antiproliferative activities. Furthermore, the 
pharmacological properties as well as therapeutic applications of coumarins 
depend upon the pattern of substitution. 
 Apart from their therapeutical activities, it is also an important analytical 
agent. Regarding their high fluorescence ability, they are widely used as optical 
whitening agents, brighteners, laser dyes and also as fluorescent probes in biology 
and medicine[12]. Being synthetically important, their biosynthetic derivatives like, 
phytoalexins, which are hydroxylated derivatives of coumarins, produced in 
carrots in response to fungal infection and can be presumed to have antifungal 
activity. General antimicrobial activity was provided in Woodruff (Galium 
odoratum) extracts[13]. 
 When coumarin ring is fused with other rings, a synergistic effect of 
biological activities of both the rings are obtained. Such compounds are exploited 
as important scaffolds for drug development. Various moieties, when combined 
with coumarin can produces same or different effects but with different 
potencies[14].  Some of the coumarin derivatives are already booming in the 
market[15].  Examples are given below in the figures (2-13) 
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O O
OH
Br
Brodifacoum (anticoagulant)
O O
OH
OH
Warfarin (anticoagulant)
OH
O
O
Difenacoum (anticoagulant)
(2) (3) (4)
 
OO
O
Auraptene 
O O
O N
O
N
O
CH3
Ensaculin 
OO
O
OH
OH
Armillarisin A 
(NMDA antagonist and a 5HT1A agonist)(antibiotic)(chemopreventative agent)
(5) (6) (7)  
 
O OO2N
O
OH
Acenocoumarol (anticoagulant)
OO OH
Hymecromone
(choleretic and antispasmodic)
O OO
O
O
Carbochromen (coronary disease)
(8)
(9)
(10)
 
OH
O
O O
Scopoletin
O O
OH
Phenprocoumon (anticoagulant)
O
O
NH2
O O
OH
O
NH
O
O
OH
O
OH
Novobiocin (antibiotic)
(11) (12) (13)
 
 Therefore, the synthesis of coumarin and its derivatives have received an 
increasing attention to synthetic organic chemists and biologists. 
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AZETIDINONES 
 The discovery of penicillin by Sir Alexander Fleming in the year 1929 is 
considered as the beginning of the antibiotic era[16,17]. The widely cited definition 
of an antibiotic as a substance produced by microorganisms, which has the 
capacity of inhibiting the growth and even of destroying other microorganisms 
was proposed by Waksman in 1942[18].  
 Azetidin-2-ones (14) are carbonyl derivatives of azetidine containing the 
carbonyl group at position 2, also called 2-azetidinone or β-lactam.  
NH
O1
2 3
4
(14)  
 Though the ring system was known since 1907, but the investigation of 
their chemistry began from 1947 only [19]. Developments in the field of β-lactams 
during the last decades indicate that the only essential feature for antibacterial 
activity in β-lactam antibiotics is the presence of the β-lactam (2-azetidinone) ring. 
 Azetidinones are currently used for chemotherapy of bacterial infections. 
The selective inhibition during cell wall synthesis of bacteria is responsible for its 
unique and lethal antibacterial action[20]. The beta-lactam ring is part of the core 
structure of several antibiotic families, including penicillins(15), 
cephalosporins(16), carbapenems(17), clavulanic acid(18), sulbactams(19) and 
tazobactams(20) which have been widely used as chemotherapeutic agents to treat 
bacterial infections and microbial diseases. 
N
S
COOH
NH
O
R
O
N
S
R'
O OH
NH
O
H
R
O
N
S
S
R
O
COOH
OH
(15) (16) (17)
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COOHH
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O OH
O
N
S
N
N N
O OH
O
(18) (19) (20)
 
 Nearly all of the antibiotics work by inhibiting bacterial cell wall 
biosynthesis. These molecules operate by forming a covalent adduct with 
membrane bound bacterial transpeptidases which are also known as penicillin 
binding proteins (PBPs) and prevent the biosynthesis of cell wall [21]. The 
biological activity of the β-lactam skeleton is generally believed to be associated 
with the chemical reactivity of the β-lactam ring as well as the substituents 
especially at the nitrogen of the β-lactam ring. The substituents at the N-1, C-3 
and C-4 position may be varied [22].  
 A smaller population of bacteria, however, may survive as there is a 
possibility of becoming resistant against beta–lactam antibiotics. They achieve 
this by expressing one of many beta–lactamase genes. More than 1000 different β-
lactamase enzymes have been documented in various species of bacteria [23]. 
These enzymes vary widely in their chemical structure and catalytic efficiencies. 
When bacterial populations have these resistant sub groups, treatment with beta–
lactam can result in the resistant strain becoming more prevalent and therefore, 
more virulent[24].  
 The continuous increase in the activity spectrum of the β-lactam antibiotics 
and also the discovery of more types of microorganisms producing them can be 
attributed to the development of more sensitive screening techniques[25]. This has 
given impetus to increased interest in synthesis and evaluation of more and more 
derivatives of β-lactam. Furthermore, the β-lactam ring also serves as a synthon or 
versatile intermediates for the synthesis of aromatic amino acid derivatives, 
peptides, polyamines, polyamino alcohols, amino sugars and polyamino ethers, as 
well as, for many biologically important classes of organic compounds[26]. Due to 
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this, the investigation into the chemistry of these compounds continues to appeal 
the synthetic and medicinal organic chemists world over. 
 
TUBERCULOSIS 
 Tuberculosis, one of the most common infections, is caused by 
Mycobacterium tuberculosis. According to the World Health Organization 
(WHO), nearly one third of the world's population has been exposed to the 
tuberculosis pathogen [27]. There are a number of known factors that make people 
more susceptible to tuberculosis infection worldwide, the most important of which 
is human immunodeficiency virus (HIV). The association of tuberculosis with 
HIV infection is so dramatic that in some cases, nearly two third of the patients 
diagnosed with the tuberculosis are also HIV-1 seropositive [28]. Smoking more 
than 20 cigarettes a day also increases the risk of tuberculosis by two- to four 
times [29]. 
 
 Unfortunately, Tuberculosis treatment has not seen much progress as 
Mycobacterium tuberculosis (Mtb) is a stubborn pathogen [30]. The available 
treatment options are few depending on a relatively small set of chemotherapeutic 
agents, which includes the widely used front-line drugs like Isoniazid, 
Ethambutol, Rifampicin, and Pyrazinamide [31]. 
 
  A number of anti-TB drugs are ineffective against TB because of the 
development of resistant strains. The limited effectiveness of current 
chemotherapy stems largely from the lengthy and complicated nature of first-line 
anti-TB drugs [32]. The most problematic issue with the current TB regimen is 
insufficient adherence to the treatment course, attributable to its length, 
complexity and adverse effects, led to difficult- and expensive to-treat multidrug-
resistant tuberculosis (MDR-TB) [33]. Treatment for MDR-TB typically requires 
18–24 months of combination therapy with second-line drugs which are less 
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efficacious, more toxic and expensive than the first-line drugs [34]. In few regions, 
almost 20% of MDR-TB cases were classified as extensively drug-resistant 
tuberculosis (XDR-TB). The treatment options for XDR-TB are very limited as 
XDR-TB bacilli are resistant not only to isoniazid and rifampicin, but also to 
fluoroquinolones and aminoglycosides [35]. More recently, another definition of 
XDR-TB as MDR-TB resistant to any fluoroquinolone and at least one of the 
second-line drugs (Capreomycin, Kanamycin and Amikacin) used in TB treatment 
[36]. There are serious adverse effects with most MDR-TB and XDR-TB drugs, 
such as nephrotoxicity and ototoxicity with aminoglycosides, hepatotoxicity with 
ethionamide and dysglycaemia with gatifloxacin. In few cases, XDR-TB has been 
shown aggressive form of TB, causing very high mortality. 
 The improvement in TB chemotherapy can be achieved by four primary 
goals: 
(i) Shorten and simplify TB treatment 
(ii)  improve efficacy, safety and reduce long-lasting therapy 
(iii) develop drugs for HIV-TB co-infection, which can be readily co-
 administered with antiretrovirals 
(iv) shorten therapy of latent TB infection . 
 Moreover, to effectively treat and control MDR- and XDR-TB patients, 
physicians and national TB treatment programs require regimens based on safer, 
tolerable and efficacious drugs having new mechanisms of action [37]. 
 The Global Alliance for Tuberculosis (GATB) drug development was 
established to address this need. Its top priority is the development of a new agent 
that will shorten the duration of chemotherapy from the current 6 – 8 months to 
two months or less. Also new drugs with activity against Mycobacterium drug-
resistant tuberculosis and latent tuberculosis are needed [38].  
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 WHO has recently launched its innovative “End TB Strategy”[39], 
supporting the TB elimination strategy and the vision of a TB-free world with 
zero death, disease and suffering due to TB. The new strategy clearly supports 
universal access to high-quality MDR-TB diagnosis and treatment. However, 
since the market launch of rifampicin in the early 1960s, no new anti-TB drug has 
been specifically developed until recently. The need for new drugs and regimens 
is obvious[40].  
 At present, the global TB development pipeline has nine candidates, but a 
key issue is how to develop them simultaneously in combination trials to identify 
the best candidate [41]. In this context, we try here to explore the ubiquitous 
heterocycle, coumarins based scaffold as promising antituberculars. 
 
Coumarin: Structural requirements for anti-TB activity [15] 
 From the published data, it is evident that coumarin nucleus substituted at 
all positions with varied substituents has produced potent anti-TB activity 
except the position 1 and 2.  
 The 3rd position of coumarin may be unsubstituted or substituents may 
vary from alkyl to aryl and heterocyclic groups. Among them, coumarin 
with flourine, n-propyl and pyrazole substituents, demonstrated excellent 
anti-TB activity.  
 Similarly, 4th position may be substituted with alkyl or bulky 
aryl/heteroaryl groups.  
 Coumarins substituted with hydroxyl group, cyclohexyl, or bulky groups 
like naphthyl, benzoazepine with indole, benzoazepine with nitro groups at 
the 4th position enhances the anti-TB activity.  
 Coumarins having substitutions at 3rd and 4th positions are found more 
because of the conjugation, and substituents may range from functional 
groups like halogens, alkene linker to heteroaryl groups.  
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 Coumarin with methyl group at the 5th position evinced much better 
activity almost like the derivatives having substitutions at 6th or 7th 
positions, which may range from functional groups like halogens, methyl 
pyridine and morpolino groups, enhances the activity.  
 Finally, the coumarin derivatives with a methyl or methoxy substitution at 
8th position show good anti-TB activity (Fig. 21). 
O O
Substituted with -F, n-propyl,the 
phenyl ring of pyrazole with -F, 
-Cl, -NO2
Sustituted with cyclohexyl, bulky 
group like naphthyl, -OH, 
benzoazepine with indole, 
benzoazepine with NO2, sulfoxide 
with benzoxazole, CH3, n-propyl
1
2
3
45
6
7
8
Unsubstituted or substituted 
with -CH3
Unsubstituted or substituted 
with pyridine, para substituted 
morpolino, -Cl, -Br, -CH3
Unsubstituted or substituted 
with -Cl, -NO2
Substituted with -CH3, -OCH3
Fig. 21. Structural requirement around coumarin nucleus for anti-TB activity  
 
Mycobacterium tuberculosis Cytochrome P450 lanosterol 14α-demethylase 
MT-CYP51  
 The cell envelope of Mycobacterium tuberculosis is unique and is 
associated with its pathogenicity[42]. Figure 22 shows a schematic representation 
of the structure of the cell envelope.  
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Figure 22. Schematic representation of the cell envelope of Mtb 
 
 Two of its most prominent features are the presence of: (a) 
arabinogalactan-mycolate covalently linked to the cell wall peptidoglycan via a 
phosphodiester bond located on the inner leaflet of the outer membrane  (b) a free 
glycolipid called trehalose dimycolate (TDM) on the surface of the cells [43]. 
 
 These particular structures provide a thick layer of lipid on the outer part 
of the cell that protects it against antibiotics, toxic chemicals and the host's 
immune system. Mycolic acids are the major constituents of this protective barrier 
and are essential for survival, virulence and antibiotic resistance [44]. Inhibitors of 
mycolic acid biosynthesis, such as isoniazid (INH), ethambutol (EMB) and 
pyrazinamide (PZA), are still in the frontline of antitubercular drugs. 
 
 The sequence of the Mycobacterium tuberculosis genome confirms the 
importance of lipid metabolism in this human pathogen. From the 4,411,529 base 
pairs, a very large proportion of the coding capacity is devoted to the production 
of enzymes involved in lipogenesis  and lipolysis [45]. The sequence of the genome 
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also revealed the existence of twenty putative cytochrome P450 enzymes, 
suggesting that at least some of these P450s could be involved in anabolism 
and/or catabolism of lipids. Of these, only CYP51B1 was functionally assigned 
based on its significant sequence similarity to eukaryotic CYP51 enzymes and its 
sterol 14α-demethylase catalytic activity. 
 A major target of antifungal azole compounds is the sterol demethylase 
(CYP51) and inhibition prevents synthesis of the membrane sterol ergosterol from 
lanosterol. This compromises membrane integrity and induces fungal cell lysis. 
 
DRUG DESIGN [46-49] 
 Drug design is a process which involves the identification of a compound 
that displays a biological profile and ends when the biological profile and 
chemical synthesis of the new chemical entity are optimized. Drug designing is 
otherwise known as rational drug design and it is a method of finding new 
medications based on the biological receptors and target molecules. It involves the 
designing of small molecules which is complementary to the biological receptor to 
which they bind and interact to cause the pharmacological actions. Modern 
method of drug designing is done with the aid of computers and hence, the 
process is known as Computer Assisted/Aided Drug Design (CADD). It uses 
computational chemistry to study about the drugs and related biologically active 
molecules. The major aim is to find whether the given molecule bind to the target 
and causes pharmacological actions or not. The basic steps involved in CADD 
are: 
 Hit identification using virtual screening. 
 Hit-to-lead optimization of affinity and selectivity. 
 Lead optimization of other pharmaceutical properties maintaining affinity. 
 
Types of Drug Design  
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 Ligand Based Drug Design 
 Structure Based Drug Design 
 
Ligand Based Drug Design (LBDD) 
 It is also known as indirect drug design. In the absence of the structural 
information of the target, ligand based method is used to know about inhibitors for 
the target receptor. Biologically active lead molecule is detected by using 
structural or topological similarity or pharmacophoric similarity properties. There 
are several criterias for similarity comparisons such as structure as well as shape 
of individual fragment or electrostatic properties of the molecule. The generated 
lead molecules are ranked based on their similarity score or obtained by using 
different methods or algorithms. 
  
Structure Based  Drug Design(SBDD) 
 It is also known as direct drug design. It depends on the knowledge of 3D 
structure of the biological target that is obtained via methods such as X-ray 
crystallography, NMR spectroscopy or homology modeling. It is used to create a 
homology model of target when the experimental structure is unavailable. With 
the three dimensional structure of the target obtained from X-ray crystallography 
or NMR spectroscopy, one can begin the search for a ligand whose orientation and 
conformation is complimentary to the receptor structure. This type of drug design 
requires the receptor’s complete structural knowledge and the tools to design 
extremely specific molecule that interact with the receptor. Therefore, structures 
of the target molecules have to be decided and the exact ligand molecule need to 
be designed.  Hence, any one of the following parameter should be available to 
start a structural based drug design: 
 3 dimensional structure of the target macromolecule 
 3 dimensional structure of a closely related analogue 
DRUG DISCOVERY METHODS[50,51] 
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1. Real screening 
2. Virtual screening 
 
Real Screening 
It include methods like high-throughput screening (HTS) which can 
experimentally check the activity of hundreds or thousands of compounds against 
the particular target limited time. Although, it is highly expensive, it provides real 
results which can be used for drug discovery. 
 
Virtual Screening 
 Virtual screening is the application of computers and computational 
methods to select or prioritize molecules for experimental screening. Thus a large 
percentage of the proposed analogs can be eliminated, and those molecules with 
the highest probability to show biological activity can be selected. By adopting 
this methodology, the time and cost associated with the production of libraries for 
screening can be considerably reduced. 
  
STEPS INVOLVED IN DRUG DESIGN [49] 
 The drug design process may be categorized into following four distinct 
stages: 
1. Selection and identification of the target. 
2. Search for lead or lead identification. 
3. Lead optimization. 
4. Synthesis of new molecules. 
 
 
 
1. Selection and identification of the target 
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 Drug discovery process begins with the identification of a possible 
therapeutic target. The selected drug target must be a key molecule involved in a 
specific metabolic or cell signaling pathway that is known or believed to be 
related to a particular disease state. 
Important drug targets include: 
 Enzymes (inhibitor- reversible or irreversible) 
 Receptors (agonist or antagonist) 
 Nucleic acid intercalators or modifiers 
 Ion channels (blockers or openers) 
 Transporters (uptake inhibitors) 
 
 The 3D structure of the protein target is usually obtained by X-ray 
crystallography [crystal structures of different macromolecules are available from 
the Research Collaboratory for Structural Bioinformatics (RCSB) Protein 
Database], Nuclear Magnetic Resonance (NMR) or homology modeling from a 
previously determined structure. 
 
2. Search for lead (lead identification) 
 Lead structures are ligands which are selected from a series of related 
compounds that exhibit suboptimal target binding affinity. After lead selection, 
they are tested for their activity towards a desired drug target. 
i) De novo molecular design 
 This approach is used to design new structures by sequentially adding 
molecular fragments to a growing structure or by adding functionality to an 
appropriately sized molecular scaffold. 
 
 
ii) Database search methods 
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The lead molecules can be selected by screening structures found in 
various chemical databases which contain an ocean of scaffolds. 
 
iii) Combinatorial methods 
Combinatorial chemistry helps to create a large library of varied molecular 
structures by using a single scaffold and diverse array of reactants. 
 
3. Lead optimization 
Lead optimization is a process in which lead compounds are altered to 
make them more effective and safer i.e., to achieve maximum affinity to the target 
with improved bioavailability and low toxicity. By effective combination of two 
or more active moieties or by elimination or substitution of various groups, the 
properties of the lead compound can be modified. 
 
DRUGLIKENESS [52,53] 
Druglikeness may be defined as a complex balance of various molecular 
properties and structural features which in turn determine whether a particular 
molecule is similar to the known drugs. 
 
In silico evaluation of druglikeness at an early stage involves the 
prediction of various ADMET (absorption, distribution, metabolism, excretion, 
toxicity) properties using computational approaches, i.e., it provides a preliminary 
prediction of the in vivo behavior of a molecule. Druglikeness score towards 
GPCR ligands , ion channel modulators, kinase inhibitors, nuclear receptor 
ligands and protease inhibitors may be evaluated online by using ‘Molinspiration 
server’. The higher the value of the score, the more the probability that the 
particular molecule will be active. 
 
LIPINSKI’S RULE OF FIVE 
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 Christopher A. Lipinski (1997) proposed four parameters that define the 
‘druglikeness’ of a potential drug candidate based on the observation that most 
medication drugs are relatively small and lipophilic molecules. Lipinski’s Rule of 
Five can be applied to evaluate druglikeness or determine if a chemical compound 
with a certain pharmacological or biological activity has properties that would 
make it a likely orally active drug in humans. Lipinski’s rule says that, in general, 
an orally active drug has not more than one violation of the following criteria: 
 
 Not more than 5 hydrogen bond donors (sum of OHs and NHs) 
 Not more than 10 hydrogen bond acceptors (sum of Ns and Os) 
 Molecular weight not greater than 500 Daltons 
 An octanol-water partition coefficient, log P, not greater than 5. 
 
Improvements  
To evaluate druglikeness in a better way, the rules have spawned many 
extensions by Ghose et al. in 1999. 
 log P                              : -0.4 to +5.6 
 Molecular refractivity   : 40-130 
 Molecular weight          : 160-500 
 Number of atoms          : 20-70 
 Polar surface area must not be greater than 140 Å 
 
 
DOCKING[54,55] 
 Docking is a method which predicts the preferred orientation of one 
molecule to a second when bound to each other to form a stable complex. 
Preferred orientation helps to predict the strength of association of or binding 
affinity between two molecules. The associations with biological molecules such 
as proteins, nucleic acids, carbohydrates and lipids play an important role in signal 
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transduction i.e. agonism or antagonism. So docking is a useful tool for predicting 
both the strength and type of signal produced. 
  
Molecular docking may be defined as an optimization program, which 
would describe the ‘best-fit’ orientation of a ligand that binds to a particular 
protein of interest. The focus of molecular docking is to computationally stimulate 
the molecular recognition process. The aim of molecular docking is to achieve an 
optimized conformation for both the protein and ligand and relative orientation 
between protein and ligand such that the free energy of the overall system is 
minimized. 
A molecular docking calculation consists of the following steps: 
 Optimization of the ligand geometry, calculation of pH-dependent partial 
 charges, and identification of rotatable bonds. 
 Calculation of electrostatic properties of the protein of interest and 
 defining the ligand –binding region. 
 Calculation of ligand-protein interaction by a scoring function that 
 includes terms and equations that describe the intermolecular energies. 
 Docking produces plausible candidate structures. These candidates musr 
be ranked by using scoring functions and to identify structures that are most likely 
to occur in nature. 
 
Rigid-body docking and flexible docking 
 If the bond angles, torsion angles and bond lengths of the components are 
not modified at any stage of complex generation, then they are known as rigid 
body docking. A rigid-body docking is sufficiently good for most docking, when 
substantial change occurs within the components at rigid-body docking. Docking 
procedures which permit flexible docking procedures or conformational change, 
must intelligently select small subset of possible conformational changes for 
consideration. 
Mechanics of docking 
Introduction 
 
 
 
 
Department of Pharmaceutical Chemistry 18 
To perform a docking screen, the first requirement is a structure of 
interested protein. Usually the structure has been measured using a biophysical 
technique such as X-ray crystallography or NMR spectroscopy. The protein 
structure and a database of potential ligands serve as inputs to a docking program. 
The success of a docking program is based on two components:  
 
 Search algorithm 
The search space includes all possible orientations and conformations of 
the protein paired with ligand. With present computing resources, it is impossible 
to exhaustively explore the search space; which involves enumerating all possible 
distortions of each molecule (molecules are dynamic and exist in an ensemble of 
conformational states) and all possible rotational and translational orientations of 
ligand relative to the protein at a given level of granularity. Most docking 
programs account for a flexible ligand, and several are attempting to model a 
flexible protein receptor. Each “snapshot” of the pair is referred to as a pose. 
 
There are many conditions for sampling the search space. Here are some 
examples: 
 Use a coarse-grained molecular dynamics simulation to propose 
energetically reasonable poses stimulation. (direct search-simplex method; 
gradient-based search-steepest descent, Fletcher-Reeves method, Newton-
Raphson method; least square methods-Marquardt method) 
 Simulated annealing (Monte Carlo search of the parameter space) 
 Use a “linear combination” multiple structures determined for the same 
 protein to emulate receptor flexibility 
 Use a genetic algorithm to “evolve” new poses that are successively more 
 fragment-based construction. 
 
 Scoring function 
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The scoring function takes a pose as input, returns a number indicating the 
likelihood that the pose represents the favorable binding interaction. 
 
Most scoring functions are physics based molecular mechanics force fields 
that estimate the energy of the pose; a low (negative) energy indicates a stable 
system and thus likely for a binding interaction. It is an alternative approach to 
derive a statistical potential for interactions from a large database of protein-
ligand complexes, such as the Protein Data Bank. This evaluates the fit of the pose 
according to this inferred potential. 
 
There are a large number of structures from X-ray crystallography for 
complexes between proteins and high affinity ligands. It is comparatively fewer 
for low affinity ligands as the later complexes tend to be less stable and therefore 
more difficult to crystallize. Scoring function trained with this data can dock hits 
(ligands predicted to bind to the protein and actually does not, when placed 
together in a test tube). 
Various softwares used for docking studies are: 
 AutoDock 
 Gold 
 Vega 
 Glide 
 Flexidock 
 Flex 
 Fred 
 Hint etc 
 
 
 
Autodock 4.2 
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Autodock is a suite of automated docking tools. It is designed to predict 
how small molecules, such as substrates or drug candidates, bind to a receptor of 
known 3D structure. Autodock uses Monte Carlo method and simulated annealing 
in combination with genetic algorithm for building the possible conformations. 
The genetic algorithm is used for global optimization. Autodock works in Linux 
platform. Cygwin is used as a user friendly interface. The local search method is 
energy minimization and Amber “force field” model helps in the evaluation of 
binding positions compatible with several scoring functions based on the free 
energy. The atomic affinity grids can be visualized. This is helpful to guide 
organic synthetic chemists to design better binders. Autodock consists of two 
main programs: 
 AutoGrid pre-calculates the grids. 
 AutoDock perform the docking of the ligand to a set of grids describing 
 the target protein. 
It also has got capabilities to visualize atomic affinity grids and its 
graphical user interface, thus to support the analysis of docking results. It has an 
advantage of getting free academic license, at the same time parallel computation 
is not supported. 
   
The aim of the present work was to synthesize new azetidine-2-one 
derivatives containing coumarin moiety in order to explore the extent of their 
antitubercular activity. The compounds were designed by in silico method using 
MT-CYP51 as the target molecule. 
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LITERATURE REVIEW 
COUMARINS 
1) Coumarins with antimicrobial activity 
a) Coumarins as antitubercular agents 
 Jeyachandran et al.,[56] (2012) synthesized a series of 4-aryl/ 
alkylsulfonylmethylcoumarins (1) and screened for in vitro antitubercular 
activity against Mycobacterium tuberculosis H37Rv (MTB) to prove their 
potential activity. 
O O
R
2
R
1
S
R
O
O
 
  (1) 
 Basanagouda et al.,[57] (2013) synthesized a series of new iodinated-4-
aryloxymethylcoumarins (2) and were screened against two mycobacterial 
strains(Mycobacterium tuberculosis H37 RV and Mycobacterium Phlei). 
                           O O
O
R
I
 
    (2) 
 
 
R – phenyl; p-methylphenyl, p-chloro phenyl; 2- 
benzoxazolyl; 2-benzimidazolyl; cyclohexyl 
R1 - H; OCH3 
R2 – H; OCH3  
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 Rezayan et al.,[58] (2012) reported synthesis of coumarin derivatives and 
their in vitro antimycobacterial activity evaluated by the broth microtiter 
dilution method against M. bovis and results were compared with  
first line anti-TB drug, ethambutol (EMB). Some of the synthesized 
compounds (3a-c) found active against M. bovis 
X
O O
NHO
OR
O
(3a-c)
a) X=H, R=Isobutyl
b) X=6-Br, R=Methyl
c) X=6-Br, R=4-Fluorobenzyl
 
 Naik et al.,[59] (2012) described the synthesis of bischromenyltriazole 
hybrids and assessed against Mycobacterium tuberculosis.  
Compounds (4a-c) were found to be highly active as streptomycin. 
 
R
O
O N
N N
O
O
O
CH3
(4a-c)
a) R=6-Cl
b) R=7-Cl
c) R=5,6-Benzo
 
 
 Virsdoia et al.,[60] (2010) described the synthesis of 4-(arylamino) 
coumarin derivatives with various aromatic amines at the C4 position of the 
coumarin under microwave condition. The compounds were evaluated for 
antimycobacterial activity against MTB H37Rv, and the results were 
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compared with standard drug Rifampin. Compound (5) was found to be the 
most potent candidate in this series. 
O
CH3
Cl
O
NH
(5)  
 Ahmad et al.,[61] (2013) synthesized a series of styrenylchromanone and 
their alkyl derivatives and reported for their anti-TB efficacy against MTB 
H37RV strain. Compounds (6a-c) were found active in the series. 
O
O
O
OR
N
N
a) R=H
b) R=
c) R=
(6a-c)  
 Patel et al.,[62] (2013) described the synthesis of coumarin-based 1,3,4-
oxadiazolebenzothiazole acetamide derivatives and assessed their anti-TB 
activities against MTB H37Rv using BACTEC MGIT method. The halo 
substituents, particularly the compound bearing iodosubstitution on the 
phenyl acetamide moiety(7a), and bearing bromo substitution on the 
benzothiazolyl acetamide moiety linked to the 1,3,4-oxadiazole core via 
sulphur linkage(7b) showed higher mycobacterial inhibitory efficacies. 
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O
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N
Br
(7a) (7b)  
 Kawate et al.,[63] (2013) investigated a series of coumarin derivatives 
conjugated with isoniazid and pyrazole moieties and evaluated their anti-
TB activity against MTB H37Rv using Resazurin MIC assay. Compound 
(8) containing a4- fluoro group at C-3 phenyl ring of pyrazole ring showed 
promising antimycobacterial potential.                 
                                
O
O
N
N
O
N
F
(8)  
 Palkar et al.,[64] (2013) synthesized a series of substituted pyridyl coumarin 
derivatives using ammonium acetate as a catalyst by one-pot method and 
tested these for their potential in vitro anti-TB activity against MTB H37Rv 
strain. Compounds (9a) and (9c) were found to exhibit potent activity than 
the compound (9b) 
O
N
O
R
R1
R2
O
R3
OH
(9a-c)
a) R=R1=R2=H, R 3=CH3
b) R=OCH3, R1=R2=H, R 3=CH3
c) R=H, R1=Br, R2=H, R 3=CH3
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b) Antibacterial activity 
 Lin et al.,[65] (2012) tested acyl coumarins, 4-hydroxy, and 7-
hydroxycoumarins and coumaric amide dimers against B. subtilis, S. 
aureus, E. coli, and Pseudomonas aeruginosa and Penicillin G potassium 
salt was used as a reference drug. Compound (10) was the most potent 
compound out of the tested compounds against Bacillus subtilis 
                                   
O O
O
CH3CH3
NH
O
(10) . 
 Zavrsnik et al.,[66] (2011) tested a series of 3-cynnamoyl-4-
hydroxycoumarins (11) on bacteria P. aeruginosa, E.oli, 
Salmonellatyphimurium, Bordatella bronchiseptica, B. subtilis and S. 
aureus. The compounds having halogens showed the highest antimicrobial 
activity. Compounds having 4-Br and 4-Cl were found to be the most 
effective against B. subtilis. Compound having 4-Cl was found to be the 
most effective against S. aureus. 
O O
OH O
R
(11)  
 Ajani et al.,[67] (2010) synthesised 3-[3-(s-aryl and s-
heteroaromatic)acryloyl]-2H-chromen-2-one derivatives (12)  and were 
screened for antibacterial activity against five gram positive bacteria 
(Bacillus anthracis, B. Stearothermophilus, B. Subtilis, B. cereus & S. 
aureus) and five gram negative bacteria (E. coli, Klebsiella pneumonia, P. 
aeruginosa, P. fluorescence & Shigella dysenteriae). 
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O O
O
X
R
X=O, NH
R=H, NO 2, Cl, CH3, C2H5
(12)  
 Kulkarni et al.,[68] (2010) synthesized some 4-azidomethyl-7-
methylcoumarin-6-sulphonamides(13) which showed very good 
antibacterial activity. 
 
NH
S
O
O
O
CH3 O
N3
R
(13)  
 
 Mashelkar et al.,[69] (2006) evaluated some 4-substituted coumarins in vitro 
against Gram positive S. aureus and Gram negative Salmonella typhi. Ampicillin 
and trimethoprim were used as standard drugs. Two compounds (14 and 15) were 
showed significant antibacterial activity against S. aureus and S. typhi. 
 
O OCH3
N
S
N
NH2
O OCH3
N
O
N
NH2
(14) (15)  
 
 
 
R=H, 3-CH3, 4-CH3, 3,4-CH3, 2,4-
CH3,              2-OCH3, 4-OCH3, 4-
Cl, 4-Br, 3-Cl, 4-CH3 
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c)  Antibacterial and antifungal activity 
 Behrami et al.,[7] (2012) evaluated 4-[(5-mercapto-4-phenyl-4H-1,2,4-
triazol-3-yl)-methoxy]-2H chromen-2-one for their antifungal and antibacterial  
activity. Two compounds (16 and 17) showed good antifungal activity against 
Aspergillus niger and Candida albicans. Compound (18) showed a significant 
antibacterial effect against S. aureus, E. coli and B. cereus 
O O
O
N
N
H
N
S
O
O
O
S
N
N
NH O O
N
NH
OH
O
OH
NH
OH
(16) (17) (18)  
 
 Mohamed et al.,[70] (2012) screened some 8-ethoxycoumarins for their in-
vitro antimicrobial activities against two Gram negative Bordetella bronchiseptica 
and E. coli and four Gram positive Bacillus pumilus, B. subtilis, S. aureus and 
Staphylococcus epidermidis pathogenic bacteria and two fungi Candida albicans 
and Saccharomyces cervesia. Compound (19) resulted in wide spectrum 
antimicrobial activity against all tested bacteria and fungi compared to ampicillin 
(25μg/ml) and mycostatin (25μg/ml). 
 
        
O
O
O
CH3
N
H
S
NC
N
NH
OCH3
Br
(19)  
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 Kudale et al.,[71] (2012) investigated a series of 3-(4-(4-(substituted 
phenyl)prop-1-ene-3-one)phenylimino) methyl)-4-chloro-2H-chromen-2-ones in-
vitro against gram positive bacteria, S. aureus, B. subtilis and S. epidermis and 
gram negative bacteria, E. coli, S. typhi and P. aeruginosa and the antifungal 
activity was evaluated against A. niger and Clostridium albicans using amoxicillin 
and fluconazole as standard drugs for antibacterial and antifungal activities 
respectively. Compound (20) was found to be most active against all the tested 
organisms. 
                   
O O
Cl
N
O
Cl
(20)  
 Kumar et al.,[72] (2010) synthesized 3-[(2’-substituted benzylidine 
aminothiazol-4’-yl)amino]coumarins and 3-[(2’-substituted benzylidine amino 
oxazol-4’-yl)amino]coumarins(21) and screened them for antibacterial and 
antifungal activities. 
O
O
NH
N
O
N
O
Cl
R
R=H, p-OH & m-OCH 3, o-OCH3
(21)  
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2.  Coumarins with Anti–inflammatory and Analgesic activity 
 Gupta et al.,[73] (2010) tested a series of 3-(2-amino-6- pyrimidin-4-yl)-6-
bromo-2H chromen-2-ones (22) for their analgesic activity . Compound having 
2,6-dichloro phenyl was found to be most promising analgesic agent devoid of 
ulcerogenic effects. 
O
Br
O
N
N
NH2
X
(22)  
 Khode et al.,[8] (2009) screened a series of 5-(substituted)aryl-3-
(3coumarinyl)-1-phenyl-2-pyrazolines (23) for their in vivo anti-inflammatory and 
analgesic activities. Some of the compounds exhibited significant analgesic 
activity and antipyretic activity with minimum ulcerogenic index. 
O O
N N
CH3
CH3
(23)  
 Kalkhambkar et al.,[74] (2007) evaluated triheterocyclic thiazoles 
containing coumarin and carbostyril(1-azacoumarin) (24) for their analgesic and 
anti-inflammatory activities. The 7-chloro substitution in carbostyril and 6,8-
dibromo substitution in the coumarin ring improved anti-inflammatory activity. 
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O
O
N
S NH
NH
O
R2
R1
(24)  
 Bylov et al.,[75] (1999) evaluated a series of N-aryl substituted 2-imino -
2H-1-benzopyran-3-carboxamides (25) and 2-oxo-2H-1-benzopyran-3-
carboxamides (26) for anti-inflammatory activity in albino rats. The results were 
found to be comparable with piroxicam taken as the reference drug.  
O NH
NH
O
R
O O
NH
O
O OH
R1
R=2-COOCH3, 4-COOCH3 R=H, 5-OCH3, 5-NO2, 5-Cl
(25) (26)  
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3.  Coumarins with Anticancer activity 
 Xin-Hua liu et al.,[11] (2010) reported the synthesis of novel coumarin 
derivatives containing 4,5-dihydropyrazole moiety (27) which exhibited potential 
antitumor activity. 
R
N N
CH3
O
O
R=4-OCH3, 4-OH, 2-Cl, H, 2,4-Cl
(27)  
 Bhattacharya et al.,[76] (2009) synthesized 4-methyl-7-hydroxy coumarin 
(28) and screened them for anticancer potential against DMBA-induced skin 
cancer in mice. 
 
O
CH3
OOH
(28)  
 Reddy et al.,[77] (2004) evaluated the effect of coumarin 3-(N-aryl) 
sulphonamides (29) on the growth of human tumor cells in culture using androgen 
receptor negative prostate (DU145), colorectal (DLD-1), non-small cell lung 
carcinoma (H157), estrogen receptor negative breast (BT20), and chronic myeloid 
leukemia (K562) cell lines.  
O O
S
O
NH
O
X'
X
(29)  
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4.  Coumarins with Antioxidant activity 
 Singh et al.,[10] (2010) tested 3-alkanoyl/aroyl/heteroaroyl-2H-chromene-
2-thiones (30) for their free radical scavenging capacity towards the stable free 
radical 2,2-diphenyl-1- picrylhydrazyl (DPPH). These compounds exhibited 
profound antioxidant activity.  
O O
R2
R3
R1
O
(30)  
 
 Roussaki et al.,[78] (2010) evaluated a series of coumarin analogues (31) 
bearing a substituted phenyl ring on position 3 for their antioxidant activity by 
using two different antioxidant assays. 
O O
R'
R
R1
R2
R3
(31)  
 
 Melagraki et al.,[79] (2009) evaluated a series of coumarin-3-carboxamides 
(32) for their in-vitro antioxidant activity and in-vivo anti-inflammatory activity. 
These derivatives were found to possess these activities. 
O O
R
OH
NH
O
X
NH2
(32)  
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5.  Coumarins with Antihyperlipidemic activity 
 Sashidhara et al.,[80] (2010) evaluated a series of coumarin bisindole 
heterocycles (33) for antihyperlipidemic activity in hyperlipidemic hamster 
model. 
O O
N
S
NH
NH
O
N
R2
R1
(33)  
 
6.  Coumarins with Anticonvulsant activity  
 Bhat et al.,[81] (2006) synthesized novel thio ureido derivatives of 
sulfonamides and thiosemicarbazido(34) derivatives of coumarin and reported 
them as potential anti-convulsant agent. 
 
O O
O
NH
NH NHR
S
R=C6H5, p-Br-C6H4, p-Cl-C6H4, p-CH3-C6H4
(34)  
 
 Siddiqui et al.,[82] (2009) tested  some heteroaryl semicarbazones (35) for 
their anticonvulsant activity using pentylenetetrazole (PTZ) induced seizure, 
maximal electroshock seizure (MES) and Neurotoxicity tests. The compounds 
having 3,4-Cl.C6H3, 2-OCH3.C6H4 and 4-Br.C6H4 exhibited significant 
anticonvulsant activity. 
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R1
(35)  
7. Coumarins with Antiparkinsonian activity 
 Matos et al.,[83] (2009) evaluated a series of 8-bromo-6-methyl-3-
phenylcoumarin derivatives (36) as MAO-A and MAO-B inhibitors using R-(-)-
deprenyl (selegiline) and Iproniazide as reference inhibitors. 
O O
Br
CH3
R
(36)  
 
8.  Coumarin with Anticoagulant activity 
 Abdelhafez et al.,[6] (2010)  synthesized  3-Pyridinyl, pyrimidinyl and 
pyrazolyl-4-hydroxycoumarin derivatives and a comparative in vivo (CT, PT 
determination) and in vitro (measurement of PIVKA-II levels) anticoagulant study 
with respect to warfarin showed that the synthesized compounds have different 
anticoagulant activities, the most prospective compounds were the 3-pyrazolyl-4-
hydroxycoumarin derivatives[6]. 
9.  Coumarin with Anti HIV activity 
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 Releva et al.,[9] (2005) synthesized 3,3’-arylidene-bis-4-hydroxy 
coumarins(37)  and were shown to exhibit good anti HIV activity. 
 
O O
OH OH
O
R
O
R=4-Br, 4-OCH3, 2-OCH3, 2,4-di OCH3, 2,3-di OCH3
(37)  
  
`Literature Review 
 
 
 
Department of Pharmaceutical Chemistry 36 
AZETIDINONES 
1. Azetidinones with Antimicrobial activity 
a) Antitubercular activity 
 Samadhiya et al.,[84] synthesized a novel series of 3-chloro-1-{[2-(6-nitro-
1H-indazol-1-yl) ethyl] amino}-4-(substituted-phenyl)- 2-azetidinones(38) and 
evaluated them for antitubercular activity against M. tuberculosis (H37Rv strain). 
O2N
N
N
N
NH
N
O Cl
Ar
Ar=Ph, 4-ClPh, 3-ClPh, 2-ClPh, 4-BrPh, 3-BrPh, 2-BrPh, 4-NO 2Ph, 3-NO2Ph
(38)  
 Sharma Ritu et al.,[85] (2011)  synthesized of N-[2-(10H-
phenothiazinyl)ethyl]-4-(phenyl)-3-chloro-2-oxo-1-iminoazetidine(39). All 
synthesized compounds were evaluated for their antibacterial, antifungal and 
antitubercular activity which displayed acceptable results. 
S
N
NHN
O
Cl
Ar
(39)  
 
 Jaju et al.,[86] (2009) synthesized a novel series of 14 new isonicotinyl 
hydrazide derivatives (40a-g), containing a 2-azetidinone nucleus. All the title 
compounds were tested for their in-vitro antimycobacterial activity against 
Mycobacterium tuberculosis H37Rv using Alamar-Blue susceptibility test. Some 
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of the compounds displayed an encouraging antimycobacterial activity profile. 
N
NH
O
N
Ar
O
Cl
(40a-g)  
 
Compound Aryl /Het. 
a 
 
b 
OH
 
c 
O  
d NO2
 
e N
 
f OCH3
 
g 
OH
OCH3
 
 
 
 
 
 Ramalakshmi et al.,[87] (2008) synthesized a novel series of 4 - aryl – 3 - 
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chloro – 1 – nicotinamido – 2 –azetidinones(41) and were screened for 
anticonvulsant and antimycobacterial activities. Antimycobacterial activity was 
screened using standard Strain H37RV and two Human Strains (Human strain-I 
and Human strain-II) isolated from patients suffering from pulmonary 
tuberculosis. 
N
NH
O
N
Ar
O
Cl
(41)  
 
Ar Ar 
2-Hydroxy phenyl 3-Hydroxy phenyl 
4-Hydroxy phenyl 3.4-Dihydroxy phenyl 
4-Methyl phenyl 4-Methoxy phenyl 
3,4,5-Trimethoxy phenyl 4-Hydroxy-3-methoxy phenyl 
4-Dimethylamino phenyl 4-Nitro phenyl 
3-Nitro phenyl 4-Chloro phenyl 
2-Chloro phenyl Cinnamyl 
 
b) Antibacterial and Antifungal 
 Chavan et al.,[88] (2013) synthesized several 2-azetidinones(42) from halo-
substituted Schiff bases using conventional as well as microwave technique. All 
compounds were screened for antimicrobial activity against Bacillus subtilis, 
Escherichia coli, Aspergillus niger and Aspergillus flavus. Most of the titled 
compounds show potent activity. 
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N
Br
OCH3
OCH3Cl
O
R
R1
R2
R3
(42)  
 Junne et al.,[89] (2012) prepared a series of 3-chloro-4-(4 - hydroxy - 5 - 
iodobiphenyl - 3 - yl) -1 (substitutedphenyl) azetidin-2-one(43a-h) derivatives and 
screened for antibacterial activity against Xanthomonas citri, E. coli, Erwinia 
carotovora and B. subtilis using penicillin G as standard antibiotic for 
comparison. 
N
R
R1R2
R3
R4
O
Cl
OH
I
(43a-h)  
Comp R R1 R2 R3 R4 Comp R R1 R2 R3 R4 
a H H NO2 H I e I H Me H I 
b H H I H NO2 f I H NO2 H I 
c H H I H Cl g Me I H NO2 H 
d H H Cl H I h Cl H I H Cl 
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 I.K. Bhat et al.,[90] (2011)  have prepared a series of N-[3-chloro-4-(4-
substitutedphenyl)-2-oxoazetin-1-yl]-2-(N’-5-methyl-3-isoxazolyl) sulphonamides 
(44) and were tested for their antibacterial and antifungal activities against four 
different bacterial cultures, viz., S. aureus, E. coli, P. aeruginosa and B. subtilis 
and one fungal culture; C. albicans. Some of the synthesized compounds showed 
remarkable antibacterial and antifungal activities as comparable to the standard 
drugs. 
S
NH
O
O
O
N
CH3
NH
NH
O
N
O
Cl
R
R=2-OHPh, 4-OMePh, 4-NMe 2Ph
(44)  
 
 Ameya A. Chavan, and Nandini R. Pai[91] (2007)  reported synthesis of 2-
{2-[3-chloro-2-(aryl)-4-oxoazetidin-1-ylamino]-acetylamino} benzothiazole-6-
carboxylic acids(45) and were screened for their anti-bacterial activity against 
S.aureus, B.subtilus, P. aeruginosa and E.coli. 
 
N
S
NH
O NH N
R
H
ClO
O
OH
(45)  
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 Mistry and Desai[92] (2005) synthesized a series of compounds 4-[spiro-
{4”-methylphenyl)-3’-methyl}-pyrazole]-3-chloro-1-(substituted benzothiazole)-
2-azetidinones(46) and were screened for their anti-bacterial activity against 
S.aureus, B.subtilus, S.typhi and E.coli. 
N
S
N
N
N
O
Cl
CH3
CH3
R
(46)  
 Srivastava et al.,[93] (2004) synthesized 1-[5'-{(2-
benzothiazolylthio)methyl}-1,3,4-thiadiazol-2-yl]-4-(substitutedphenyl)-3-chloro-
2-oxoazetidine(47) as antimicrobial and anthelmintic agents. 
 
N
S
S
N
S
N
N
O
Cl
R2
R1
(47)  
 
 Desai et al.,[94] (2004) synthesized 4-substituted phenyl-1-[2-(2,4,6-
trichlorophenoxymethyl)-1,3,4-thiadiazol-5-yl]3-chloro-2-azetidinone (48) and 
screened for their antibacterial activity. 
S
N
N
O
NCl
Cl
Cl
O
Cl
Ar
(48)  
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 Thakar et al.,[95] (2003) have synthesized 4-Aryl-3-chloro-1-(3’,5’-
dichloro-2’benzo(b) thio phenoylamino)-2-azetidinones(49) and evaluated their 
antimicrobial activity against E.coli, S.aureus, P.vulgaris and A.niger. 
S
Cl
Cl
NH
O
N
O
R
Cl
(49)  
 
2. Azetidinones with Analgesic and Antiinflammatory activity  
 Chhajed et al.,[96] (2012) synthesized a series of 1-(2-(1H-benzimidazol-2-
yl) phenyl) – 3 – chloro – 4 - (un/substituted -phenyl) azetidin-2-ones(50) and 
screened them for analgesic and anti-inflammatory activities on acetic acid 
induced writhing in mice and carrageenan induced paw edema in rats 
N
N
H
N
O
Cl
R
R=H, 2-Cl, 4-Cl,4-F, 2-OH, 4-OH, 2-NO 2, 4-OMe
(50) . 
 Shanmugapandiyan et al.,[97] (2010)  prepared series of 2-[4-(azetidin-2-
one)-3-Chloro-4-phenyl]-1H-Phenylbenzimidazoles(51a-h)  and the compounds 
were screened for antibacterial, antifungal, analgesic activity by writhing reflex 
method and anti-inflammatory activity by carrageenan induced paw edema 
method. 
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N
N
H
N
O
Cl
R1
R2
R3
(51a-h)  
Comp. No. R1 R2 R3 
a -H -H -H 
b -H -Cl -H 
c -H -OH -H 
d -H -CH3 -H 
e -H -N(CH3)2 -H 
f -H -OCH3 -H 
g -OCH3 -CH3 -H 
h -OCH3 -OCH3 -OCH3 
 
3. Azetidinones with Anticancer activity 
 O’Boyle et al.,[98] (2011) have synthesized a series of azetidin-2-ones(52) 
substituted at positions 1, 3 and 4 of the azetidinone ring scaffold via the 
Staüdinger reaction and evaluated for antiproliferative, cytotoxic and tubulin-
binding activity. 
N
OMe
MeO
MeO
O
R
CH3 OMe
R=2-Thienyl, 3-Thienyl
(52)  
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4. Azetidinones with Antihyperlipidemic activity 
 Jain et al.,[99] (2013) have synthesized a series of novel 2-[1 (substituted 
phenyl) - 4-oxo-azetidin-2-yl]-5, 6-disubstitutedthieno [2, 3-d] pyrimidin-4(3H)-
ones(53) and were evaluated for their lipid lowering activity in Wistar albino rats. 
Some of them showed significant lipid lowering effects. 
 
NH
NS
R2
R1
O
N
O
R3
R1,R2=aryl, cycloalkyl, H etc; R 3=alkyl, halo etc
(53)  
 
 
5. Azetidinone with Anticonvulsant activity 
 Pratap Y Pawar et al.,[100] (2012)  synthesized 10 derivatives of 2-
azetidinones(54) and were evaluated for in vitro anticonvulsant activity. Most of 
the compounds exhibited mild to moderate anticonvulsant activity. 
 
HOOC
N
O
Cl
R
(54)  
 
 
 Vijaya Kumar MM J et al.,[101] (2009) synthesized novel N-Substituted-3- 
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Chloro-2- Azetdinones(55) as potential anticonvulsant agents. These newly 
synthesized heterocyclics showed promising anticonvulsant activity. 
 
N
H
S
NH
C
O
N
O
Cl
OH
OCH3
(55)  
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CHEMISTRY 
 
CHEMISTRY OF COUMARINS 
 Coumarins are naturally occurring oxygen heterocycles. They contain a 
benzo-α-pyrone (2H-1-benzopyran-2-one) nucleus as the main structural unit [1]. 
                                                             
O O
1
2
3
45
6
7
8  
                                                         2H-1- benzopyran-2-one 
 Coumarins are classified on the basis of their chemical structure into the 
following types: 
 Simple coumarins: Coumarin  and its hydroxylated, alkoxylated, alkylated 
derivatives and their glycosides (scopoletin umbelliferone) 
 Furanocoumarins: Coumarins containing a furan ring fused to the 
benzopyrone nucleus including  dihydrofurocoumarins, (psoralen, 
bergapten) 
 Pyranocoumarins: six membered ring analogues of furocoumarins  
 (Xanthyletin ) 
 Coumarins substituted in the pyrone ring: 3 or 4 substituted coumarins like 
4-hydroxycoumarins (V), 4-phenylcoumarins (VI) and 3, 4-
benzocoumarins (VII). 
 Isocoumarins: lactones of benzenecarboxylic acids with a hydroxylated 
 side chain unsaturated in the β-position, isomeric with coumarins. 
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METHODS FOR THE SYNTHESIS OF COUMARIN DERIVATIVES[102,103] 
 Of the number of synthetic methods, there are a few which have yielded 
important results; there are several others whose applications are less general. All 
these methods center round the possibility of building up the pyrone ring on a 
suitable benzene derivative. 
 
1. Knovenagel Reaction 
 Condensation of ortho-hydroxy aldehydes with active methylene 
compounds (diethyl malonate, malanonitrile) in the presence of a base (ammonia 
or amines) to form coumarins is known as Knovenagel reaction. 
 
CHO
OH
+
O
OROR
O base
O
COOR
O
o-hydroxy aldehyde active methylene compound 3-substituted coumarin
 
When malonic acid and piperidine are used, the reaction is called Doebner 
modification 
 
2. Perkin reaction 
 It involves the formation of coumarins by aldol condensation of an 
aromatic ortho-hydroxy benzaldehyde with acid anhydrides in the presence of an 
alkali salt of an acid. 
 
CHO
OH
+
O
O CH3CH3
O NaOAc
O O
o-hydroxy aldehyde acid anhydride
coumarin
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3. Pechmann  Reaction 
It is the condensation of phenols with β-ketoesters  in the presence of an 
acid catalyst (sulphuric acid). This is the most widely used method for the 
synthesis of coumarins. 
R1 OH
+
R2
O
R3
O
O
CH3
O
CH3
CH3
OCH3
substituted phenol -keto ester
H2SO4
3,4,7-trisubstituted coumarin 
  
When acetoacetic ester and its derivatives are used, the reaction is referred 
as Pechmann - Duisberg reaction. 
 
4. Wittig reaction 
In this method, carbonyl compounds and phosphonium ylides react to form 
an alkene whose lactonisation will give coumarin derivatives. 
 
R
CHO
OH
+ Ph 3P=CHCOOEt
Et2NPh
reflux
R
COOC2H5
OH lactonisation
R
O O  
 
5. Kostanecki – Robinson Reaction 
In this reaction, coumarins (usually 3 and 4 substituted) are formed by 
acylation of o-hydroxy aryl ketones with aliphatic acid anhydrides followed by 
cyclisation.  
O
R1
OH
+
R2
O
O
R2
O
R2CH2COONa
O
O
R1
O
R2
cyclisation
O
R1
R2
O
-hydroxy aryl ketone
acid anhydride
3,4-disubstituted coumarin 
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6. Reformatsky Reaction 
In this, coumarins are obtained by the lactonisation of the β-hydroxy ester 
formed from the reaction between aldehydes or ketones with organozinc 
derivatives of α-haloesters. 
 
      
R
O
OH
+
Br
O
O
CH3
Zn
OH
R
CH2COOC2H5
BrZnO
H3O
+
R
CH2COOC2H5
OH
OH
lactonisation
O O
R
carbonyl compound -haloester
 
 
 
PROPERTIES OF COUMARINS[104] 
I) Physical Properties 
Synonym        : 1,2-Benzopyrone, 2H-1-Benzopran-2-one 
Chemical formula: C9H6O2 
Melting point        : 71ͦ C 
Boiling point         : 301ͦ C 
Density         : 0.935 g/cm 3 
Dipole moment     : 4.51D 
Solubility         : Slightly soluble in water and ethanol 
  Soluble in chloroform, diethyl ether, pyridine 
Coumarin in alkaline medium exhibits a green fluorescence in UV light. It 
has the characteristic odour of vanilla beans and is used for the preparation of 
perfumes, soaps and flavouring agents. 
II) Chemical Properties[105] 
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Reactivity of Coumarins 
Coumarin and its derivatives are highly reactive because of the aliphatic 
moiety present in the coumarin, it is likely to undergo ring opening at the acyl 
centre. Carbon-6 on the aromatic ring can undergo electrophilic attack such as 
Friedel-Crafts acylation, sulphonation leading to the formation of 6-substituted 
derivatives. A methyl substituent on the coumarin nucleus may react differently 
depending on the position of attachment. Phenol group present in the C-7 position, 
easily undergo acylation, benzoylation and Friedel-Crafts reactions. 
 
Reactions of coumarin nucleus 
A. With Nucleophiles 
 Several kinds of nucleophiles react with coumarins. Some of these 
reactions involve ring opening and occasionally, recyclisation into another ring. A 
nucleophile (Nu) which cleaves the ring, attacks and breaks one of the bonds of 
the ring oxygen atom as shown below. 
O
Nu
O
-
a
O O
b a
b
O
O
-
Nu
 
 
 
 
 
 
 
 
 
1. With C-Nucleophiles 
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a. Grignard Reagents 
 Coumarins react with Grignard reagents, like esters, and give mixture of 
products, resulting from the ring opening of the initial carbonyl adduct. 
 
O OH
MeMgI
Et2O / 0 
oC
O OMgI
CH3
CH3
O
OMgI
O CH3
CH3
CH3OH
CH3
OH
10% 40%  
b. Diazomethane 
On reaction with nucleophilic carbon of diazomethane, 3-cyano and 3-
nitrocoumarin are readily converted into their 4-methyl homologues but coumarin 
is transformed into the pyrazolone. 
 
O O
R CH2N2 , 20 
oC
O O
R
CH3
R=CN, 92%
R=NO 2, 59%
R=H; CH2N2
0 oC
COOMe
OMe
NN
O
 
c. Methylsulphinylmethide 
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Carbanions generated in situ by strong bases cleave pyran-2-one rings but 
acidification may result in the formation of a new compound.  
 
 
O
OMe
O
+ MeSOCH 2
-
Na
+
OMe
CH2SOCH3
O
ONa
H+
O
OH
OH
OSMe
O
O
CH2SOCH3
chromone  
2. With N-Nucleophiles 
a. Aliphatic Primary and Secondary Amines: 
Coumarins do not react with ammonia and amines to produce α-
quinolones, even under forced conditions. The reaction is not favourable since it 
involves a non-aromatic intermediate. 
b. Aromatic Primary and Secondary amines 
Coumarins react with primary aromatic and secondary cyclic amines to 
yield substitution products such as 4-arylamino and 4-piperidino coumarin. 
O
NHAr
O O O
OH
PiperidineArNH2
O
N
O
 
 
 
3. With O-Nucleophiles 
Reaction with alkali 
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The reaction of coumarins with hydroxides involves initial addition to the 
carbonyl carbon, followed by opening of the lactone ring to give yellow solutions 
of the salts of the corresponding cis-cinnamic acids (coumarinic acids). 
 
O O
COO
-
Na
+
O
-
Na
+
dil.NaOH
hot
acid
COOH
OH
2-Hydroxy-cis-cinnamic acid  
B. With Electrophiles 
a. Chloromethylation 
            Chloromethylation occurs at C-3 position of coumarins by the reaction 
with formaldehyde in the presence of HCl or acetic acid and ZnCl2. 
O O
CH2O / HCl
AcOH / ZnCl2
O O
CH2Cl
 
b. Bromination 
             Coumarin reacts with one molecule of bromine to form th3,4-dibromide 
which readily eliminates hydrogen bromide to form 3-bromocoumarin. Reaction 
with bromine, in the presence of excess of aluminium chloride, yields 6-
bromocoumarin. 
O O
Br2 / CHCl3
O
Br
Br
H
H
O
-HBr
O
Br
O
Br2 / AlCl3
O O
Br
 
c. Sulphonation 
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  Sulphonation of coumarin with chlorosulphonic acid at 100  ͦC yields the 
6-sulphonyl derivative, but at 130-140 ͦC, a second substituent is introduced to 
give 3,6-disulphonyl chloride. 
O O O O
ClO3S
O
SO3Cl
O
ClO3S
ClSO3H
100 oC
ClSO3H
160 oC
 
d. Nitration 
Nitration occurs mainly at C-6 position and under vigorous conditions, 
substitution occurs at C-3 position also. 
 
O O O O
O2N
O
NO2
O
O2N
HNO3
100 oC
HNO3
160 oC
 
 
e. Mannich reaction [106] 
Mannich reaction of 4-hydroxy coumarin with primary amines and 
formaldehyde resulted in the formation of 3-aminomethyl-4-hydroxycoumarins.  
 
O O
OH
N
R
R'
O
OH
O
NH R'
R
HCHO
 
 
Similarly, Mannich reaction of 3-hydroxy coumarin with formaldehyde 
and primary or secondary amines resulted in 4-N,N-dialkylaminomethyl-3-
hydroxy coumarins. 
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O O
OH NH R'
R
HCHO
O O
OH
N
R
R'
 
C. Reduction 
a. Catalytic redction 
Catalytic reduction of coumarin under suitable conditions results in the 
formation of either 3.4-dihydroxy coumarin or the open ring product which can be 
cyclised efficiently. 
 
O
CH3
O
OMe
CH3
CHMeCH 2COOEt
CH3
OMe
CH3 PPA O
CH3
O
OMe
CH3
 
 
b. Reduction with Diborane and Hydrogen peroxide 
Reduction with diborane followed by hydrogen peroxide has two effects 
on coumarins: the carbonyl group is reduced to methylene and the elements of 
water are added across the 3,4-double bond in an anti-Markonikow manner but the 
overall yield is very low. 
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O O
i. B2H6
ii. H2O2 O
OH
3,4-dihydro-H-chromen-3-ol 
 
c. Reduction with Lithium aluminium hydride 
Hydride reagents can react either at carbonyl carbon or the conjugate 
position and therefore mixtures of two compounds are produced. 
O O
CH2OH
OH
LiAlH4
Et2O
+
CH2OH
OH
 
 
D. Hydrolytic Reaction 
Coumarins hardly undergo hydrolysis by alkali to form coumarinic acids 
which are cis in form and can be converted to trans form by prolonged treatment 
with alkali.  
 
O O
NaOH
HCl
H
OH
COONa
COONa
OH
H
 
On the other hand, substituted coumarins give a mixture of a phenol and a 
ketone as a result of hydrolysis with alkali. 
 
O O
OH
CH3
Ph
33-50% KOH
OH OH
+ CH3COCH2Ph
 
E. Diels Alder Reaction 
Chemistry 
 
 
 
 
Department of Pharmaceutical Chemistry 57 
Coumarins serve as dienophiles in Diels Alder reaction, but only under 
relatively strong conditions. 
O O
+
CH2
CH3 CH2
CH3
Xylene / 260 oC
O O
H
H
CH3
CH3
 
 
F. Reactions with Radicals 
The C-3 position of coumarin is most susceptible to attack by radicals. 
Coumarin is arylated at C-3 by treatment with 4-nitrobenzenediazonium chloride 
under Meerwein reaction conditions. Variation of solvent and pH showed that 
acetone with a buffered pH of 2-4 gave the best results. 
 
O O
+
O O
NO2
NO2
N2
+
Cl
-
Cu2+
 
 
G. Ring Contraction Reaction 
The reaction is a type of Perkin rearrangement reaction. The reaction 
proceeds with the bromination of coumarins. The resultant dibromocoumarin on 
alkaline degradation gives coumarilic acid which is decarboxylated to benzofuran. 
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O O
Br2
O O
Br
Br
KOH
-H2O O
-
Br
COO
-
O
COOH
Distillation
-CO2
-Br-
O
 
H. Photochemical Reactions [104] 
The photodimerisation of coumarin has been studied in several solvents 
and the nature of solvent has an effect on this complex reaction. 
 
1. In a polar medium such as methanol, the only product formed is the cis 
 head to head isomer. 
2. In a non-polar medium such as benzene or dioxane, trans head to head 
dimer is the main product of the reaction; small amounts of head to tail 
dimers are also formed in non-polar solvents. 
O O
h, MeOH
O
O
H
H
O
H
H
O
h C6H6
O
O
H
H
O
H
H
O
+
O
O
O
O
cis head to head isomer
head to tail isomertrans head to head isomer  
I. Vilsmeier-Haack Reaction 
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The reaction of an N,N-disubstituted formamide, such as DMF or N-
methyl formanilide, with acid chlorides, such as phosphoryl chloride or phosgene, 
leads to the formation of an 'adduct’. These adducts are usually referred to as the 
Vilsmeier reagent which is used in the formylation of electron rich aromatic 
compounds or olefins.  
 
Formation of adduct: 
N
CH3
CH3 H
O
DMF
POCl3
N
+
CH3
CH3 H
OPOCl2
Cl
-
N
+
CH3
CH3 H
Cl
-OPOCl2 
Vilsmeier-Haack Reaction in 4-hydroxy coumarin: 
O
OH
O
POCl3
DMF O
OH
O
N
+
H
CH3
CH3
H2O / OH
-
O
OH
CHO
O
3-formyl-4-hydroxy coumarin 
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CHEMISTRY OF AZETIDINONES [107-109] 
 The parent heterocyclic ring of azetidinones is azetidine.Azetidine is a 4 
membered heterocyclic ring system with nitrogen as hetero atom. 2-Azetidinones 
are also knownas β-lactams and it is one of the most common heterocyclic rings 
found in antibiotics. 2-Azetidinones consists of a carbonyl group on the second 
position. 
NH
O1
2
34
 
 
Properties of Azetidin-2-ones 
Azetidin-2-ones are moisture sensitive, colourless solids with melting 
point in the range of 73-74 ͦ C. X-ray crystallographic studies of a number of 
monocyclic azetidin-2-ones indicate that the ring is essentially planar with the 
nitrogen atom slightly out of the mean plane of its substituents except where steric 
factors enforce greater deviations from planarity.  
 
In normal amides, C=O shows a distance of 1.32Å, but azetidinones shows 
a distance of 1.38. The increased distance is the reason for angle strain. The IR 
spectra of monocyclic β-lactams have absorption maxima in the region of 1730-
1760 cm-1 while the fused 2 and 3 cepham systems show IR maxima in the region 
of 1772-1784 cm-1. 
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METHODS FOR THE SYNTHESIS OF AZETIDINONES 
1. From non-heterocyclic precursors by closure of one bond: 
i) Formation of N-C(2) bond: 
The thermal cyclization of β-amino acids to β-lactams fails because of β-
elimination resulting in deamination, although there is a report of preparation of 
the parent compound. 
R NH
R'
COOH PCl3
or SOCl2
N
R
O
R'
1,4-disubstituted -lactam 
ii) From β-amino acid esters: 
Ring closure between β-amino ester of Grignard reagent is generally used 
to produce β-lactam. The yield is about 50-70%. Further reaction of the Grignard 
reagent with the carboxyl group is prevented because of the hindered nature of the 
Grignard reagent. 
 
NH
O
H2C
H2C
NH2
COOR1
+ R2MgX
H2C
H2C
NH
COOR1
 
iii) Formation of N-C(4) bond 
A number of examples of cyclization of N-substituted 3-halopropanamides 
in the presence of strong base like NaNH2 or KNH2 to give β-lactams have been 
reported. 
 
R1
X
CONHR 2 NaNH2
N
R1
OR2
+ R1
CONHR 2
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2. From non-heterocyclic precursors by closure of two bonds 
i) Formation from [3+1] fragments 
Formation of the β-lactam by the reaction of the dianion with methylene 
diiodide provides an example of a [3+1] type of ring closure. 
 
H5C6S
NR
O
CH2I2
N
H5C6S
O R
 
ii) Formation from [2+2] fragments 
 The reaction is also called as ketene-imine cycloaddition was reported by 
Staudinger as a smooth well documented route for β-lactam derivatives. Ketenes, 
on reaction with imines through a non-photochemical 2+2 cycloaddition ,will 
yield β-lactam. 
 
Mechanism 
STEP-1 
Schiff’s base formation 
The mechanism for imine formation is essentially a two-step process. The 
first is the addition of the nucleophilic amine to the partially positive carbonyl 
carbon, followed by the loss of a proton by the oxygen. Next is the protonation of 
the OH group, which then can be lost as water in an elimination reaction. 
C H
O
+ NH2 NH R
fast
CH
O
-
H2N NH R
fast
CH
OH
NH NH R
fast
CH
OH2
NH NH R
H
+
CH
HN NH R
+
+
fast
-H+
C H
N NH R
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STEP-2 
Azeitidinone formation 
The mechanism involved in a particular case may well depend on the 
reactants and the timing of mixing. 
One possible mechanism involve prior formation of a ketene from acid 
chlorides in the presence of bases such as triethylamine, which interacts with 
imines resulting in cycloaddition reaction. 
H
R
1R
2
Cl
O
B-
C
C
O
R
1
R
2
ketene
C
N
R
5
R
3
R
4
+
imine
N
R5
R
4
R
2
O
R
3
R
1
 
Another mechanism is also proposed that involves the interaction of the 
imine with the acid chloride to give an immonium ion. This is then cyclized by 
deprotonation under the influence of the base. 
 
H
R
1
R
2
X
O
+ NR
5
R
3
R
4
NR5
R
3
R
4
H
R
2
R
1
O
+
deprotonation
N
R
5
R
4
R
3
R
1
R
2
O
 
3. Formation of N-C(4) and C(2)-C(3) bonds: 
The [2+2] cycloaddition of isocyanates to alkenes provides one of the best 
routes to β-lactams. 
 
CH3
CH3
CH3
CH3
+ RN C O
N
CH3
CH3
RO
CH3
CH3
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4. Miscellaneous routes to azetidin-2-ones 
i) Ring expansion 
Ring expansion reaction of cyclopropanones leads to β-lactams via the 
cyclopropanolamine.
O RCH(NH2)CO2C2H5
NHOH CH
R
CO2C2H5
C4H9OCl
NH
+
OH CH
R
CO2C2H5
Cl
Ag+
N
O
CH CO2C2H5
R
Cyclopropanones cyclopropanolamine
 
 
ii) Ring contractions 
Several ring contraction routes to β-lactams have been developed. One of 
the most important is the Wolf rearrangement of 3-diazopyrrolidine -2,4-diones to 
give 3-carboxy azetidin-2-ones. 
NR1
O
N2
O
R3
R2
h
N
R2
R3
R1O
O
H2O
N
R2
R3
R1O
HOOC
 
iii) From Azetidines 
Azetidin-2-carboxylic acid is treated with oxalyl chloride to give the 
azetinium salt, followed by the reaction with MCPBA and pyridine. 
NR
HOOC
ClCOCOCl
NR
+
Azetinium salt
MCPBA
Pyridine
NR
H
O
OCOAr
NR
O
 
iv) Wasserman Cyclisation 
Chemistry 
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 A halogen β- to the carbonyl would increase the IR absorption of the 
C=O, one of the criteria of the reactivity of the β-lactam. β-Bromopropionamide 
derivative was prepared, which can be cyclized by wasserman procedure using 
sodium hydride to give the N-(3-carboxy-6-methylphenyl)-3-difluoro-2-
azetidinone. 
BrCH2COCOOEt
SF4
BrCH2CF2COOEt
ClSO3H
Cl
Br
O
F
F
H2NAr
NH
CH3F
F
O
CH3
COOH
NaH
N
F
F
O
CH3
COOH  
 
REACTIONS OF AZETIDINONES 
1) Ring opening reactions 
β-aminopropionic acid is obtained from β-lactam in the presence of a base. 
The β-lactam ring is also susceptible to the action of alcoholic hydrochloric acid. 
 
NH
O
CH3NH2 / 
OH
-
HCl / C 2H5OH
HOOC
NH2
NH2 NH
O
CH3
EtOOC
NH3
+
Cl
-
 
2) Reduction 
Chemistry 
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Azetidinones on reduction with LiAlH4 undergoes cleavage of the ring to 
form aminoalcohol. 
N
O
CH3
LiAlH4 N
CH3
H
O
-
HOH2C
NH
CH3
 
 
3) Formation of N-Derivatives 
The N-substituted azetidin-2-ones undergo facile N-substitution to yield 
products which can be further manipulated to give derivatives of β-lactams. 
NH
O
NaNH 2 / NH3
HNO 2 / CH3OH
RBr
RCOCl / C5H5N
15 oC
N
O
R
O
RO=C
O
ON
 
4) Reaction with phosphorus pentasulphide  
β-lactams are converted to thiolactams on reacting with P2S5 in benzene at 
25 ͦC. 
 
N
O
H5C6
C6H5
H
H
NH2
P2S5 / Benzene
25 oC
N
O
H5C6 C6H5
H
NH2
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PURPOSE OF THE STUDY 
 Tuberculosis (TB) is the most common cause of the death from infectious 
disease world-wide, which affects mainly the poorest countries of the world. Cell 
wall of Mycobacterium tuberculosis includes peptidoglycans and complex lipids 
(mycolic acids) which are significant determinant of its virulence. Novel 
antitubercular drugs are urgently needed because TB remains a global health 
priority [110]. 
 Coumarin compounds as medicinal drugs have been increasingly attracting 
special interest due to their potential outstanding contributions in the prevention 
and treatment of diseases, and the related researches and developments have  
received an increasing attention to synthetic organic chemists [110]. A great deal of 
effort has been made directly or indirectly towards the discovery and  
development  of  coumarin-based  antitubercular drugs  and  some  excellent  
achievements  have  been  acquired. 
 Azetidinone  is  an  exciting  pharmaceutical  fragment  in  drug discovery.  
The  strong  activity  of  the  famous  antibiotics  such  as  penicillins,  
cephalosporins,  thienamycins,  nocardicins,  aztreonams  as  well  as  
carbapenems  is  attributed  to  the  presence  of  the  2 -azetidinone  ring [110].  
 Mycobacterium tuberculosis  genome has high number of cytochrome 
P450 enzymes and parallel studies indicated that cytochrome P450 inhibiting 
azole drugs has potent antitubercular activity. Recent research explains potential 
drug target on Mycobacterium tuberculosis P450 and provides  
evidence for roles of selected P450 isoforms in host lipid and sterol or steroid 
transformations [111]. 
Purpose of the Study 
 
 
 
 
Department of Pharmaceutical Chemistry 68 
 Drug discovery tools help in designing new molecular entities which are 
safe and effective without consuming much of the research hours. The purpose of 
the present work was to design and synthesize new azetidine-2-one derivatives 
containing coumarin moiety in order to explore the extent of their antitubercular 
activity. The compounds were designed by in silico method using MT-CYP51 as 
the target molecule. 
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PLAN OF WORK 
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DOCKING STUDIES OF THE LEAD 
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OF THE SYNTHESIZED COMPOUNDS 
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EXPERIMENTAL SECTION 
IN SILICO STUDIES 
Softwares and Databases used 
 Accerlys discovery studio viewer 
 Molinspiration server 
 Accelrys accord for excel 
 RCSB protein data bank 
 Online SMILES translator 
 Autodock 4.2 which combines 
 Autodock tools 
 Python molecule viewer 1.5.6 
 Vision 1.5.6 
 Cygwin 64 
TARGET SELECTION 
The present study was focused on antimycobacterial activity. From the 
literature review and the current research on CYP51 inhibitors, we have selected 
cytochrome P450 lanosterol 14α-demethylase in Mycobacterium tuberculosis as the 
target for the present study. The pdb structure of MT-CYP51 was downloaded from 
the RCSB protein data bank. 
LEAD SELECTION  
The lead azetidin-2-one, imidazolidin-2-one, oxazolidin-2-one and 
thiazolidin-2-one  derivatives of coumarin were selected based on several literature 
reviews. 
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DOCKING STUDIES FOR THE LEAD 
Aim   : To predict the bioactivity score of the ligands. 
Database  : RCSB protein data bank 
Protein selected : MT-CYP51 (1EA1) 
 Target proteins were downloaded from RCSB protein data bank and 
docking studies were performed. 
Steps involved in docking studies [55,112,113] 
Docking process is done with AutoDock 4.2 
 Conversion of refined enzyme into pdb format 
 Conversion of pdb format of ligand into pdbqt format 
 Preparation of grid box by setting grid parameters 
 Docking process by setting docking parameters 
 Saving the docked result as dlg file 
  Viewing the docked conformation 
 Taking snapshots of the interactions 
STEP I: 
Protein structure refinement  
 MT-CYP51 enzyme was downloaded from RCSB Protein Data Bank (PDB) 
and the enzyme was refined before docking. The steps involved are: 
 Open Accelrys discovery studio viewer. 
 File OpenSelect the enzyme file downloaded from RCSB PDB. 
 Click View option and then click Hierarchy. 
 Click water molecules. 
 Click water molecule  Select all water moleculescut. 
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 Select ligand, which is unnecessary and cut. 
 Save the molecule in a desired location 
 
STEP II 
Ligand file format conversion 
 The ligands which are desired are drawn in ChemSketch software. 
 Tools Click Generate Cick SMILES notation (Simplified Molecular 
 Input Line Entry System, which is a file format). 
 Save the SMILES in a word document. 
 Open the online smiles translator –cactus. nci.nih.gov/services/ translate/ 
 Upload the SMILES. 
 By choosing the required file format and save the file in a pdb format 
 (e.g.:ligand.pdb). 
 Online smiles translator allows the user to convert SMILES format into 
PDB, MOL, SDF and smile text file format. Thus the selected ligand molecule of 
canonical smile format was converted to pdb format. 
 The protein and ligand files which are prepared by above said procedures 
are taken for docking. 
STEP III 
Docking with autodock 4.2 
 Docking calculation in AutoDock was performed using the refined protein 
and the desired ligand in pdb format. 
 
 Preparation and running a docking programme 
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Preparing the protein 
 Open autodock 4.2 
 Open fileClick read moleculeChoose the particular refined enzyme 
 file. 
 The elimination of the water is carried by the following steps.  
 Press Select option 
 Click Selectclick select from string option 
 Then write “*HOH*” in the Residue line &“*” in the atom line. 
 Click Add No new selection and then dismiss.          
 Addition of  hydrogens is done by, 
 Press Edit  option 
 Click the Hydrogens 
 Then click Add 
 Choose all Hydrogen, No Bond Order, and ‘yes’ to renumbering click 
 Ok. 
 Next click Edit optionclick add the Kollmann Charges. 
 Then save the enzyme molecule as 1ea1refined.pdb 
 Select Edit DeleteDelete all molecule 
Preparing the ligand 
 Confirm that all the hydrogens are added in the ligand. 
 Toggle the Auto Dock Tools button. 
 Open the Ligand Click Input and choose the suitable ligand file and 
 finally open. 
 The torsions are designed by following steps, 
 In the Ligand option select Torsion Tree  
Experimental  Section 
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 Select  Detect Root option 
 Click Torsion Tree 
 Then select the Choose Torsions option 
 Amide bonds should NOT be active. 
 After that click the Torsion Tree and select Set Number of Torsions 
 Number of rotatable bonds is chosen. 
 Finally Save the Ligand files by selecting the Output option (pdbqt file). 
 Select Edit DeleteDelete all molecule. 
 
Conversion of pdb files of protein into pdbqt file  
 Select the Grid option and open the Macromolecule pdb file. 
 Auto Dock adds the Charges and itself merges the Hydrogens. 
 Save the object as pdbqt in desired area. 
 
AutoGrid Calculation and creating “gpf” file 
 Open the grid and click Macromolecule option and choose the rigid 
 protein then yes to preserve the existing charges.  
 The Preparation of grid parameter file is carried out by, 
 Open Grid 
 Select the Set Map Types 
 Choose Ligand 
 Accept it. 
 Setting of  grid properties, 
 Open Grid 
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 Select the Grid box 
 Set the proper Grid Dimensions(60.60.60) 
 Adjust the Spacing 
 Select the File and click Close Saving Current. 
 Save the grid settings as gpf file in the input option (ligand.gpf). 
 After running the grid file, the output automatically save as ‘glg’ file 
Auto Dock calculation and creating ‘dpf’ file: 
 The rigid molecule specification is carried out by, 
 Select the Docking option 
 Click the Macromolecule  
 Set Rigid File Name. 
 The ligand specification is carried out by, 
 Click the Docking option 
 Select the ligand  
 And then Accept it. 
 In the next step, click Docking option and select Search Parameters in that 
 click Genetic Algorithm and finally accept it. 
 ClickDocking options Select Docking ParametersChoose the 
 Defaults. 
 Click Docking optionSelect Output and adds Lamarckian Genetic 
 algorithm (LGA). 
 Save the docked settings as ‘dpf’ file in the input option (ligand.dpf) 
 After running the docked file, the output automatically saves as ‘dlg’ file. 
Programming of ‘Auto Grid’ and ‘Auto Dock’execution: 
1. Open Cygwin and typed as follows: 
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  cd c: 
  cd cygwin 
  cd usr 
  cd local 
  cd bin 
            Program should list out the pdb, pdbqt, gpf and dpf files of an enzyme and 
ligand molecule. 
2. Then type as: 
 ./autogrid4.exe <space> -p <space>ligand.gpf –l <space>ligand.glg 
           If a ligand gets into the spacing of the grid, then the execution of this 
command will be;  
   ‘Successful completion’. 
3. Then type as: 
 ./autodock4.exe<space> -p<space>ligand.dpf –l<space>ligang.dlg 
 If the ligand binds to the amino acids through 10 different conformations, 
then the execution of this command will be; ‘Successful completion’. 
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STEP IV  
Viewing docking results  
Reading the docking log file .dlg 
 Toggle the AutoDock Tools button 
 Click Analyze and Open Dockings. 
 In the next step, click Analyze option and Conformations then Load. 
 Double click on the conformation for to view it. 
Visualizing docked conformations 
 Click Analyze and Dockings then play. 
 Load dlg file  
 Choose the suitable conformations 
 In the next step, click Analyze and Docking then Show Interactions. 
Obtaining snap shots of docked pose  
 Open the File and Read the Molecule  
 Open Analyze Click Dockings and Open dlg file  
 Open Analyze Click Macromolecule and Choose pdbqt file. 
 Open Analyze Click Conformations and Load  
 Double click the desired conformation 
 Click Analyze and Docking then Show Interactions. 
 Proteins and ligand interaction will be displayed. Zoom it and increase the 
 contrast by holding right key and ctrl. 
 Open FileSave imagecygwin/usr/local/bin as .png 
 The above mentioned steps involved in docking are done for all the 150 
 ligands (az1-42, im1-36, ox1-36 and th1-36) 
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RESULTS AND DISCUSSION 
 The docking results of MT-CYP51 (1EA1.pdb) with the ligands az1-42, 
im1-36, ox1-36 and th1-36 and standard (fluconazole) are reported in the Tables 
1-4. The best docked structures should have the binding energy lower to the 
standard. The binding sites and the active sites are shown in the snapshots. 
Table 1. Binding energies of az1-42 
Sl. No. 
Compound 
code 
Binding 
energy 
(Kcal/mol) 
Sl.No. 
Compound 
code 
Binding 
energy 
(Kcal/mol) 
1 az1 -10.51 22 az22 -10.5 
2 az2 -10.8 23 az23 -10.36 
3 az3 -10.34 24 az24 -10.45 
4 az4 -10.7 25 az25 -10.4 
5 az5 -10.6 26 az26 -11.15 
6 az6 -10.47 27 az27 -8.94 
7 az7 -10.2 28 az28 -8.75 
8 az8 -9.54 29 az29 -7.46 
9 az9 -9.94 30 az30 -11.22 
10 az10 -10.32 31 az31 -8.15 
11 az11 -11.15 32 az32 -8.32 
12 az12 -9.47 33 az33 -9.27 
13 az13 -10.77 34 az34 -8.73 
14 az14 -10.67 35 az35 -8.44 
15 az15 -11.02 36 az36 -8.44 
16 az16 -11.03 37 az37 -11.28 
17 az17 -11.03 38 az38 -11.24 
18 az18 -10.97 39 az39 -10.43 
19 az19 -10.83 40 az40 -9.99 
20 az20 -10.77 41 az41 -9.88 
21 az21 -8.62 42 az42 -10.01 
Fluconazole -6.67 
 
 
 
Table 2. Binding energies of im1-36 
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Sl.No. 
Compound 
code 
Binding 
energy 
(Kcal/mol) 
Sl.No. 
Compound 
code 
Binding 
energy 
(Kcal/mol) 
1 im1 -11.19 19 im19 -9.96 
2 im2 -11.08 20 im20 -10.84 
3 im3 -10.9 21 im21 -10.85 
4 im4 -10.52 22 im22 -11.21 
5 im5 -10.79 23 im23 -11.05 
6 im6 -10.72 24 im24 -9.08 
7 im7 -10.73 25 im25 -9.17 
8 im8 -9.47 26 im26 -8.72 
9 im9 -10.31 27 im27 -8.73 
10 im10 -10.5 28 im28 -8.72 
11 im11 -11.05 29 im29 -9.48 
12 im12 -10.31 30 im30 -9.89 
13 im13 -10.56 31 im31 -9.77 
14 im14 -11.14 32 im32 -8.96 
15 im15 -11.13 33 im33 -10.14 
16 im16 -10.94 34 im34 -8.54 
17 im17 -11.24 35 im35 -10.37 
18 im18 -9.79 36 im36 -10.11 
Fluconazole -6.67 
 
 
 
 
 
 
Table3. Binding energies of ox1-36 
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Sl.No. 
Compound 
code 
Binding 
energy 
(Kcal/mol) 
Sl.No. 
Compound 
code 
Binding 
energy 
(Kcal/mol) 
1 ox1 -11.2 19 ox19 -11.25 
2 ox2 -10.76 20 ox20 -11.17 
3 ox3 -10.96 21 ox21 -10.23 
4 ox4 -10.97 22 ox22 -11.24 
5 ox5 -11.08 23 ox23 -10.99 
6 ox6 -11.23 24 ox24 -11.2 
7 ox7 -11.2 25 ox25 -11.25 
8 ox8 -10.34 26 ox26 -10.79 
9 ox9 -11.15 27 ox27 -11.21 
10 ox10 -11.16 28 ox28 -11.18 
11 ox11 -11.27 29 ox29 -8.9 
12 ox12 -10.59 30 ox30 -11.16 
13 ox13 -10.59 31 ox31 -9.29 
14 ox14 -11.24 32 ox32 -9.11 
15 ox15 -11.27 33 ox33 -8.49 
16 ox16 -10.02 34 ox34 -8.3 
17 ox17 -11.23 35 ox35 -8.36 
18 ox18 -10.37 36 ox36 -9.59 
Fluconazole -6.67 
 
 
 
 
 
 
Table 4. Binding energies of th1-36 
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Sl.No. 
Compound 
code 
Binding 
energy 
(Kcal/mol) 
Sl.No. 
Compound 
code 
Binding 
energy 
(Kcal/mol) 
1 th1 -10.91 19 th19 -11.26 
2 th2 -10.83 20 th20 -11.23 
3 th3 -10.93 21 th21 -11.25 
4 th4 -10.66 22 th22 -10.43 
5 th5 -10.58 23 th23 -10.65 
6 th6 -11.05 24 th24 -11.25 
7 th7 -10.83 25 th25 -10.87 
8 th8 -10.29 26 th26 -11.23 
9 th9 -9.98 27 th27 -11.25 
10 th10 -9.97 28 th28 -10.76 
11 th11 -11 29 th29 -11.11 
12 th12 -10.19 30 th30 -11.26 
13 th13 -10.7 31 th31 -9.32 
14 th14 -10.89 32 th32 -9.69 
15 th15 -11.02 33 th33 -10.67 
16 th16 -11.13 34 th34 -8.46 
17 th17 -11.27 35 th35 -8.45 
18 th18 -11.13 36 th36 -9.75 
Fluconazole -6.67 
 
 The binding energy of all the 150 compounds selected were found to be 
lower than that of the standard (fluconazole). In this project, we are only concerned 
with the azetidinone series (az1-36) of compounds. In the series, the binding energy 
of az38 (-11.28) is the lowest. Hence, twelve compounds with similar structure as 
that of az38 is selected for further studies. This series include az31-42 and for ease, 
we rename them as N1-6 and P1-6.   
  Binding of fluconazole with MT-CYP51 
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 Fluconazole interacts with MT-CYP51 at ARG 96, ALA 256, MET 99, 
TYR 76, THR 260 and HEM 460. Binding energy was found to be -6.67 kcal/mol. 
 
Figure 1.Snapshot of fluconazole binding with 1EA1 
Binding of az31-42 with MT-CYP51 
az31 (N1) 
 N1 interact with MT-CYP51 at ARG 96, ALA 256, MET 99 and HEM 460. 
Binding energy was found to be -8.15 kcal/mol. 
 
Figure 2.Snapshot of N1 binding with 1EA1 
 
 
az32 (N2) 
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 N2 interact with MT-CYP51 at ARG96, ALA 256, THR 260 and HEM 460. 
Binding energy was found to be -8.32 kcal/mol. 
 
Figure 3.Snapshot of N2 binding with 1EA1 
 
az33 (N3) 
 N2 interact with MT-CYP51 at ARG96, ALA 256, TYR 76 and HEM 460. 
Binding energy was found to be -9.27 kcal/mol. 
 
Figure 4.Snapshot of N3 binding with 1EA1 
 
 
az34 (N4) 
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 N4 interact with MT-CYP51 at ALA 256, TYR 76, THR 260 and HEM 460. 
Binding energy was found to be -8.73 kcal/mol. 
 
Figure 5.Snapshot of N4 binding with 1EA1 
az35 (N5) 
 N5 interact with MT-CYP51 at ALA 256, TYR 76 and HEM 460. Binding 
energy was found to be -8.44 kcal/mol. 
 
Figure 6.Snapshot of N5 binding with 1EA1 
 
 
 
az36 (N6) 
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 N6 interact with MT-CYP51 at ALA 256, TYR 76 and HEM 460. Binding 
energy was found to be -8.44 kcal/mol. 
 
Figure 7.Snapshot of N6 binding with 1EA1 
 
az37 (P1) 
 P1 interact with MT-CYP51 at ALA 256, TYR 76, THR 260 and HEM 460. 
Binding energy was found to be -11.28 kcal/mol. 
 
Figure 8.Snapshot of P1 binding with 1EA1 
 
 
az38 (P2) 
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 P2 interact with MT-CYP51 at ALA 256, TYR 76, THR 260 and HEM 460. 
Binding energy was found to be -11.24 kcal/mol. 
 
Figure 9.Snapshot of P2 binding with 1EA1 
 
az39 (P3) 
P3 interact with MT-CYP51 at ALA 256, TYR 76, ARG96, THR 260 and 
HEM 460. Binding energy was found to be -10.43 kcal/mol. 
 
Figure 10.Snapshot of P3 binding with 1EA1 
 
 
az40 (P4) 
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 P4 interact with MT-CYP51 at ALA 256, TYR 76, THR 260 and HEM 460. 
Binding energy was found to be -9.99 kcal/mol. 
 
Figure 11.Snapshot of P4 binding with 1EA1 
az41 (P5) 
 P5 interact with MT-CYP51 at ALA 256, TYR 76, THR 260 and HEM 460. 
Binding energy was found to be -9.88 kcal/mol. 
 
Figure 12.Snapshot of P5 binding with 1EA1 
 
 
 
az42 (P6) 
Experimental  Section 
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 P5 interact with MT-CYP51 at ALA 256, TYR 76, THR 260 and HEM 460. 
Binding energy was found to be -10.01 kcal/mol. 
 
Figure 13.Snapshot of P6 binding with 1EA1 
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TOXICITY STUDIES 
 Pharmacokinetic properties of the selected lead compounds were checked 
to ensure the safety and efficacy of the compounds. 
Toxicity studies are performed by two methods: 
 Evaluation of drug likeness property 
 Evaluation of ADME data 
Evaluation of drug likeness properties [114] 
For the better oral absorption of the ligands, the drug likeness scores are 
constructed by getting information about the solubility, diffusion, Log P, molecular 
weight etc. One of the ideal method for this is using Lipinski’s rule of five with the 
Molinspiration server. 
Calculation of Lipinski’s rule of five 
1. Open the Molinspiration home page. 
2. Click calculation of molecular properties and prediction of bioactivity. 
3. Draw the structure of N1 in JME window or paste the smile notation of the 
 compound. 
4. Then click calculate properties. 
5. Save the properties. 
6. JAVA program is required in the computer for the calculation of the 
 properties. 
Calculation of properties of the rest of the compounds is done in the same manner.  
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RESULTS AND DISCUSSION 
Table 5: Drug likeness scores of N1-6 and P1-6 using molinspiration server 
Sl.No. 
Compound 
code 
mLogP MW 
No. of H 
acceptors 
No. of 
H 
donors 
No. of 
violations 
1 N1 -0.10 385.76 8 2 0 
2 N2 0.74 370.75 7 1 0 
3 N3 2.21 342.74 6 1 0 
4 N4 1.82 342.74 6 1 0 
5 N5 1.82 343.73 7 1 0 
6 N6 -0.04 385.76 8 2 0 
7 P1 1.38 427.42 8 2 0 
8 P2 2.21 412.40 7 1 0 
9 P3 3.69 384.39 6 1 0 
10 P4 3.30 384.39 6 1 0 
11 P5 3.30 385.38 7 1 0 
12 P6 1.43 427.42 8 2 0 
 
In addition to ligand-protein complex modeling, in vivo absorption 
capabilities of the designed molecules were tentatively assessed by means of 
Lipinski’s rule of five that predicts that a compound administered orally will more 
likely have a good absorption or permeation. All the compounds satisfy the rule 
which indicates that all the ligands N1-6 and P1-6 have good oral absorption.   
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IN SILICO ADME STUDIES OF THE DOCKED LIGAND 
 ADME studies are performed to evaluate the absorption, distribution, 
metabolism of the selected ligands using Accord for Excel server. 
Procedure 
 2 D structures were directly introduced into Accord for Excel for carrying 
out ADME studies by using Edit Chemistry module of software. Then the structure 
is subjected to Function module and the data for descriptors like blood brain barrier 
penetration (BBB), human intestinal absorption (HIA), plasma protein binding, 
aqueous solubility and hepatotoxicity were calculated. 
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Table 6: ADME data of N1-6 and P1-6 
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N1 109.0717 -2.87356 3 8.407494 -1.6156 3 0 0.267327 0.8537 1 0.807947 0 3.226168 2 0 
N2 96.2615 -3.6258 3 5.779164 -1.06074 3 0 0.405941 1.993101 1 0.774834 0 1.635727 2 0 
N3 78.9607 -3.69516 3 2.561484 -0.74286 3 1 0.514851 2.1359 1 0.860927 0 0.367197 2 0 
N4 78.9607 -3.79516 3 2.561484 -0.90949 3 0 0.425743 1.5968 1 0.860927 0 0.460503 2 0 
N5 90.2217 -3.2166 3 4.30963 -1.12077 3 0 0.425743 1.4897 1 0.934437 0 1.109506 2 0 
N6 109.0717 -2.87364 3 8.407494 -1.6156 3 0 0.29703 0.8537 1 0.940397 0 3.226168 2 0 
P1 1099.0717 -3.58 3 8.917111 -1.32435 3 1 0.643564 1.7960022 1 0.940397 0 3.117621 1 0 
P2 96.2615 -4.45063 2 7.29044 -0.76948 3 1 0.693069 2.9354 1 0.940397 0 2.469873 0 0 
P3 78.9607 -4.56566 2 3.555211 -0.45161 2 1 0.712871 3.07820 1 0.92053 0 0.991146 2 0 
P4 78.9607 -4.09475 2 2.831851 -0.61823 3 1 0.782178 0.539101 1 0.874172 0 0.511625 2 0 
P5 90.2217 -4.0871 2 4.898544 -0.82951 3 1 0.534653 2.432 1 0.92053 0 1.282406 2 0 
P6 109.0717 -3.58008 3 8.91711 -1.32435 3 1 0.643564 1.796001 1 0.913907 0 3.11762 1 0 
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SYNTHESIS 
MATERIALS AND METHODS 
Reagents and chemicals used: 
 4-Hydroxy coumarin, Phosphorous oxychloride, Dimethyl formamide, 
soniazid, Nicotinamide, 2-Amino pyridine, 4-Amino pyridine, 2-Amino pyrimidine, 
Nicotinic hydrazide, Ethanol, Dioxane, Triethylamine, Chloroacetyl chloride,  
Phenylacetyl chloride 
 All the reagents and chemicals were procured from Sigma Aldrich High media 
and Lobachem. All the compounds procured were purified and dried, whenever 
necessary before use, following standard methods. 
Apparatus used: 
 Beakers, test tubes, glass rods, mechanical stirrer, thermometer, round bottom 
flask, reflux condenser, conical flasks, separating funnel, dropping funnel and pipettes. 
Analytical work: 
 Melting point was determined by using melting point apparatus MR-VIS, 
 visual melting range apparatus, LABINDIA and uncorrected. 
 Reactions were monitored by thin layer chromatography (TLC) on a pre-
 coated silica gel G plated using Iodine vapor as visualizing agent. 
 UV spectra were recorded on JASCO V-530 UV-VIS spectrometer in the 
department of Pharmaceutical analysis, College of Pharmacy, SRIPMS, 
Coimbatore. 
 IR  spectra were recorded on JASCO FTIR-420 series in the department of 
Pharmaceutical Analysis, College of Pharmacy, SRIPMS, Coimbatore. 
 NMR spectra were recorded on Bruker AVANCE III 500MHz NMR 
 spectrometer at SAIF, IIT, Madras.  
 Mass spectra were recorded on JEOL GCMATE II GC-MS spectrometer at 
 SAIF, IIT, Madras. 
SCHEME 
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O
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O
POCl3 , DMF
O
OH
CHO
O
4-Hydroxy coumarin 3-Formyl-4-hydroxy coumarin 
+ RNH2
Primary amino compound
Ethanol
O
OH
O
N
RDioxan, TEA
ClCH2COCl
O
OH
N
R
Cl
O
O
N1-6
S1-6
Dioxan, TEAPhCH2COCl
O
OH
O
N
Ph
R
O
P1-6  
Compound code R 
S1, N1 , P1 
N
NH-
O
 
S2, N2 , P2 
N
C-
O
 
S3, N3 , P3 
C-
N
 
S4, N4 ,P4 
C-
N
 
S5, N5 ,P5 
C-
N
N
 
S6, N6 , P6 
N
NH-
O
 
Procedure 
Step 1: Synthesis of 4-hydroxy-3-formyl coumarin [115] 
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  The compound was prepared from 4-hydroxycoumarin under Vilsmeier 
conditions (POCl3/DMF). An amount of 9.72 g (0.6 mol) of 4-hydroxycoumarin was 
dissolved in DMF (46.2 ml). In this mixture, at -5 ͦ C, POCl3  (0.18 mol) was added 
slowly. The reaction mixture was stirred at 60 ͦ C for 1hr. This mixture was kept 
overnight at 0 ͦC. The precipitate was hydrolyzed by boiling with 5% Sodium carbonate 
solution. The yellow product obtained was filtered and recrystallized from ethanol. 
Step 2: Synthesis of Schiff base from formyl coumarin (S1-6) [116] 
 Equimolar quantities of 4-hydroxy-3-formyl coumarin and primary amino 
compound (RNH2) was dissolved in ethanol and refluxed for 2hrs. It was then cooled 
and poured into crushed ice. The product formed was obtained by filtration and 
recrystallised from ethanol. 
Step 3: [117] 
Synthesis of Chlorine substituted Azetidinones (N1-6 )  
 A mixture of 0.01 mol Schiff bases (S1-6) and triethyl amine (0.025 mol) was 
dissolved in dioxane (10 ml) and stirred. To this well stirred solution, chloroacetyl 
chloride (0.025mol) was added drop by drop for a period of 30 min at 0-5 ͦ C. The 
reaction mixture was further stirred for 6hrs. It was then kept at room temperature for 
48hrs.The reaction mixture is poured into crushed ice and the resultant product (N1-6) 
was filtered and washed with water, dried and recrystallized from DMSO.  
Synthesis of Phenyl substituted Azetidinones (P1-6 ) 
 A mixture of 0.01 mol schiff bases (S1-6) and triethyl amine (0.025 mol) was 
dissolved in dioxane (10 ml) and stirred. To this well stirred solution, phenylacetyl 
chloride (0.025mol) was added drop by drop for a period of 30 min at 0-5 ͦ C. The 
reaction mixture was further stirred for 6hrs. It was then kept at room temperature for 
48hrs.The reaction mixture is poured into crushed ice and the resultant product (N1-6) 
was filtered and washed with water, dried and recrystallized from DMSO.  
 
PHYSICAL CHARACTERISATION DATA        
1)  Substituted 3-Chloro azetidin-2-ones                       
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                                        O
OH
N
R
Cl
O
O  
Table 7: Physical characterization of substituted 3-Chloro azetidin-2-ones 
Comp. 
code 
R 
Molecular 
formula 
Molecular 
weight (g/mol) 
% 
Yield 
Melting 
point 
Rf 
value 
N1 
N
NH
O
 
C18H12ClN3O5 385.75 77 252-253 0.57 
N2 
N
O
 
C18H11ClN2O5 370.74 77 167-168 0.66 
N3 
N
 
C17H11ClN2O4 342.73 78 66-67 0.55 
N4 
N
 
C17H11ClN2O4 342.73 74 134-35 0.43 
N5 
N
N
 
C16H10ClN3O4 343.72 73 108-109 0.41 
N6 
N
NH
O
 
C18H12ClN3O5 385.75 75 236-237 0.77 
Recrystallisation       :  Dimethyl sulfoxide 
Solvent system         :   Chloroform : Water (5.5:4.5) 
Visualizing agent     :   Iodine vapour 
2)  Substituted 3-Phenyl azetidin-2-ones 
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O
OH
O
N
Ph
R
O
 
Table 8: Physical characterization of substituted 3- Phenyl azetidin-2-ones 
Comp. 
code 
R 
Molecular 
formula 
Molecular 
weight 
(g/mol) 
% 
Yield 
Melting 
point 
Rf 
value 
P1 
N
NH
O
 
C24H17N3O5 427.40 75 162-164 0.32 
P2 
N
O
 
C24H16N2O5 412.39 76 220-221 0.51 
P3 
N
 
C23H16N2O4 384.38 75 85-86 0.78 
P4 
N
 
C23H16N2O4 384.38 74 140-141 0.60 
P5 
N
N
 
C22H15N3O4 385.37 74 212-213 0.39 
P6 
N
NH
O
 
C24H17N3O5 427.40 75 218-219 0.70 
Recrystallisation       : Dimethyl sulfoxide 
Solvent system         : Chloroform : Water (3:7) 
Visualizing agent     : Iodine vapour 
SPECTRAL ANALYSIS OF COMPOUNDS [118-120] 
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 The structures of synthesized compounds during the present investigation were 
established on the basis of chemical data IR, UV, NMR and MASS spectral data. The 
purity of the compounds was established by single spot on TLC plates. 
COMPOUND  CODE : N1 
 
O
OH
O
N
NH
Cl
O
N
O
 
Chemical name 
3-chloro-4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-1-
(pyridine-4-carboxamido)azetidin-2-one 
UV Spectrum 
Solvent used : DMSO 
λmax  : 273nm 
IR (KBr, vmax in cm-1) 
3433.64 (Alcoholic O-H), 1727.91 (lactam C=O), 1671.02 
(Carbonyl C=O), 1608.34 (Amide C=O), 1553.38 
(Aromatic C=C), 1185.04 (C-N), 887.095 (C-Cl) 
1H NMR spectral data 
8.297 (bs, 1H, N-H), 5.313 (d, 1H, Cl-CH-CO), 7.321-
7.763(m, 8H, Aromatic H and Pyridyl H)   
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Mass Spectral Data 
Molecular weight of the compound : 385 
Sl. No. Fragments m/z values 
1 
O
OH
O
N
NH
Cl
O
N
O
+
 
385 
2 
O
OH
O
CH3
+
 
176 
3 
O
OH
O
+
 
162 
4 
NH2
N
O
+
 
121 
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Figure 14:UV Spectrum of  N1 
 
Figure 15:IR Spectrum of N1  
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Figure 16: NMR Spectrum of N1 
 
 
Figure 17: Mass spectrum of N1 
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COMPOUND  CODE : N2 
 
O
OH
O
N
Cl
O
O N
 
Chemical 
name 
3-chloro-4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-1-(pyridin-3-
ylcarbonyl)azetidin-2-one 
UV Spectrum 
Solvent used : DMSO 
λmax  : 274nm 
IR (KBr, vmax 
in cm-1) 
3428.81 (Alcoholic O-H), 1714.41 (lactam C=O), 1649.8 (C=O), 
1608.34 (Amide C=O), 1555.31 (Aromatic C=C), 1185.04 (C-N), 
888.059 (C-Cl) 
1H NMR 
spectral data 
5.319 (d, 1H, Cl-CH-CO), 4.969 (d, 1H, -N-CH-C-Cl), 7.269-
8.156(m, 8H, Aromatic H and Pyridyl H)   
 
 
 
 
 
 
 
Mass Spectral Data 
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Molecular weight of the compound : 370 
Sl. No. Fragments m/z values 
1 
O
OH
O
N
Cl
O
O N
+
 
370 
2 
O
OH
O
CH3
+
 
176 
3 
O
OH
O
+
 
162 
4 
NH2
N
O
+
 
121 
 
 
Figure 18: UV spectrum of N2 
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Figure 19: IR Spectrum of N2 
 
 
 
Figure 20: NMR Spectrum of N2 
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Figure 21: Mass Spectrum of N2 
 
 
 
 
COMPOUND  CODE : N3 
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O
OH
O
N
N
Cl O
 
 
Chemical name 
3-chloro-4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-1-(pyridin-2-
yl)azetidin-2-one 
UV Spectrum 
Solvent used : DMSO 
λmax  : 269nm 
IR (KBr, vmax in 
cm-1) 
3426.89 (Alcoholic O-H), 1724.05 (lactam C=O), 1663.3(C=O), 
1530.24 (Aromatic C=C), 1326.79 (Aromatic C-N),  
1179.26 (C-N), 888.059 (C-Cl) 
 
 
 
 
 
 
 
 
 
Figure 22: UV Spectrum of N3 
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Figure 23: IR Spectrum of N3 
 
 
 
COMPOUND  CODE : N4 
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O
OH
O
N
N
Cl O
 
 
Chemical name 
3-chloro-4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-1-
(pyridin-4-yl)azetidin-2-one 
UV Spectrum 
Solvent used : DMSO 
λmax  : 274nm 
IR (KBr, vmax in cm-1) 
3432.67 (Alcoholic O-H), 1728.87 (lactam C=O),  
1671.98 (C=O), 1554.34 (Aromatic C=C), 1307.5 
(Aromatic C-N), 1185.04 (C-N), 888.059  (C-Cl) 
 
 
 
 
 
 
 
 
 
Figure 24: UV Spectrum of N4 
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Figure 25: IR Spectrum of N4 
 
 
 
COMPOUND  CODE : N5 
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O
OH
O
N N
N
Cl O
 
Chemical name 
3-chloro-4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-1-
(pyrimidin-2-yl)azetidin-2-one 
UV Spectrum 
Solvent used : DMSO 
λmax  : 272nm 
IR (KBr, vmax in cm-1) 
3479.92 (Alcoholic O-H), 1730.8 (lactam C=O),  
1661.37 (C=O), 1542.77 (Aromatic C=C), 1306.54 
(Aromatic C-N), 1193.72 (C-N), 888.059  (C-Cl) 
 
 
 
 
 
 
 
 
 
Figure 26: UV Spectrum of N5 
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Figure 27: IR Spectrum of N5 
 
 
 
 
COMPOUND  CODE : N6 
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O
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N
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Chemical name 
3-chloro-4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-1-
(pyridine-3-carboxamido)azetidin-2-one 
UV Spectrum 
Solvent used : DMSO 
λmax  : 273nm 
IR (KBr, vmax in cm-1) 
3425.92 (Alcoholic O-H), 1729.83 (lactam C=O),  
1672.95 (C=O), 1556.27 (Aromatic C=C), 1185.04 (C-N), 
889.023  (C-Cl) 
 
 
 
 
 
 
 
Figure 28: UV Spectrum of N6 
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Figure 29: IR Spectrum of N6 
 
 
 
COMPOUND  CODE : P1 
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O
OH
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N
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O
 
Chemical name 
4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-phenyl-1-
(pyridine-4-carboxamido)azetidin-2-one 
UV Spectrum 
Solvent used : DMSO 
λmax  : 273nm 
IR (KBr, vmax in cm-1) 
3448.1 (Alcoholic O-H), 1721.16 (lactam C=O), 
1634.38 (C=O), 1607.38 (Amide C=O), 1555.31 
(Aromatic C=C), 1185.04 (C-N),  
1H NMR spectral data 
5.325 (d, 1H, Cl-CH-CO), 7.266 (bs, 1H, N-H), 7.419-
8.161(m, 13H, Aromatic H and Pyridyl H)   
 
 
 
 
 
Mass Spectral Data 
Molecular weight of the compound : 427 
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Sl. No. Fragments m/z values 
1 
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Figure 30: UV Spectrum of P1 
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Figure 31: IR Spectrum of P1 
 
 
 
Figure 32: NMR Spectrum of P1 
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Figure 33: Mass Spectrum of P1 
 
 
 
COMPOUND  CODE : P2 
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O
OH
O
N
O
O
N
 
 
Chemical name 
4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-phenyl-1-
(pyridin-3-ylcarbonyl)azetidin-2-one 
UV Spectrum 
Solvent used : DMSO 
λmax  : 273nm 
IR (KBr, vmax in cm-1) 
3414.35 (Alcoholic O-H), 1729.83 (lactam C=O), 1644.02 
(C=O), 1607.38 (Amide C=O), 1555.31 (Aromatic C=C), 
1186.97 (C-N) 
 
 
 
 
 
 
 
 
Mass Spectral Data 
Experimental  Section 
 
 
 
Department of Pharmaceutical Chemistry 119 
Molecular weight of the compound : 412 
Sl. No. Fragments m/z values 
1 
O
OH
O
N
O
O
N
+
 
412 
2 
O
OH
O
+
 
162 
3 
O O
CH3
+
 
174 
 
 
 
 
 
 
Figure 34: UV Spectrum of P2 
Experimental  Section 
 
 
 
Department of Pharmaceutical Chemistry 120 
 
Figure 35: IR Spectrum of P2 
 
 
 
 
Figure 36: Mass Spectrum of P2 
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COMPOUND  CODE : P3 
Experimental  Section 
 
 
 
Department of Pharmaceutical Chemistry 122 
 
O
OH
O
N
N
O
 
Chemical name 
4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-phenyl-1-
(pyridin-2-yl)azetidin-2-one 
UV Spectrum 
Solvent used : DMSO 
λmax  : 261nm 
IR (KBr, vmax in cm-1) 
3428.81 (Alcoholic O-H), 1726.94 (lactam C=O), 1637.27 
(C=O), 1567.84 (Aromatic C=C), 1182.15 (C-N)  
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Figure 37: UV Spectrum of P3 
 
Figure 38: IR Spectrum of P3 
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COMPOUND  CODE : P4 
O
OH O
N N
O  
Chemical name 
4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-phenyl-1-
(pyridin-4-yl)azetidin-2-one 
UV Spectrum 
Solvent used : DMSO 
λmax  : 273nm 
IR (KBr, vmax in cm-1) 
3439.42 (Alcoholic O-H), 1730.8 (lactam C=O), 1671.02 
(C=O), 1556.27 (Aromatic C=C), 1186.01 (C-N)  
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Figure 39: UV Spectrum of P4 
 
 
Figure 40: IR Spectrum of P4 
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COMPOUND  CODE : P5 
 
O
OH O
N
N
N
O  
Chemical name 
4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-phenyl-1-
(pyrimidin-2-yl)azetidin-2-one 
UV Spectrum 
Solvent used : DMSO 
λmax  : 274nm 
IR (KBr, vmax in cm-1) 
3450.99 (Alcoholic O-H), 1729.83 (lactam C=O), 
1629.55 (C=O), 1556.27 (Aromatic C=C), 1186.01  
(C-N) 
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Figure 41: UV Spectrum of P5 
 
 
Figure 42: IR Spectrum of P5 
 
 
 
COMPOUND  CODE : P6 
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Chemical name 
4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-phenyl-1-
(pyridine-3-carboxamido)azetidin-2-one 
UV Spectrum 
Solvent used : DMSO 
λmax  : 268nm 
IR (KBr, vmax in 
cm-1) 
3372.89 (Alcoholic O-H), 1729.83 (lactam C=O), 1638.23 
(C=O), 1610.27 (Amide C=O), 1565.92 (Aromatic C=C), 
1185.04 (C-N) 
 
 
 
 
 
 
 
Figure 43: UV Spectrum of P6 
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Figure 44: IR Spectrum of P6 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIMICROBIAL STUDIES 
Experimental  Section 
 
 
 
Department of Pharmaceutical Chemistry 130 
ANTIBACTERIAL SCREENING [121] 
Apparatus and chemicals required 
Sterile swab   : Hi Media 
Non-absorbent cotton  : Rama Raju Surgical cotton Ltd. 
Conical flask   : Borosil 
Test tubes   : Borosil 
Petri dishes   : SD Fine-Chem Ltd. 
Micropipettes   : VARI pipettes (Hi-Tab Lab) 
Autoclave   : Universal Autoclave 
Laminar Air Flow unit : CLEAN AIR Instruments Inc. 
Microtips   : Tarsons 
The antibacterial screening was carried out in the Pharmaceutical 
Biotechnology laboratory, College of Pharmacy, SRIPMS, Coimbatore. 
Media used 
Mueller Hinton agar which is gelled with 2% agar (bacteriological grade) is 
used as the medium for the antibacterial screening. 
The Mueller Hinton contain the following ingredients:- 
Casein enzymic hydrosylate :  17.5 g/l 
Beef infusion   :  300 g/l 
Soluble starch                          :          1.5 g/l 
Agar     :          17.00 g/l 
Final pH at 25°C  : 7.4(±0.2) 
Media preparation and sterilization 
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  The ingredients were dissolved in distilled water with the aid of heat and the 
pH was adjusted to 7.4(±0.2) by using dilute acid or alkali. 
 30-35 ml of Muller Hinton agar was transferred to Petri plates and sealed. The 
media is autoclaved at a pressure of 15 psi (121°C) for not less than  
15 minutes. 
Microorganisms used 
 Staphylococcus aureus NCIM 2079, Bacillus subtilis NCIM 2063, Escherichia 
coli NCIM 2918 and Pseudomonas aeruginosa NCIM 2036 were procured from 
National Chemical Laboratory, Pune and stored in the Pharmaceutical 
Biotechnology laboratory, College of pharmacy, SRIPMS, Coimbatore. 
 The strains were confirmed for their purity and identity by Gram’s staining 
method and their characteristic biochemical reactions. 
 The selected strains were preserved by sub culturing them periodically on 
nutrient agar slants and storing them under frozen conditions. 
 For antimicrobial study, fresh 24 hr broth cultures were used after the 
standardization of the culture. 
 Drugs used                  :  N1-6, P1-6(500µg/ml) 
 Standard drugs :  Ciprofloxacin (5µg/ml) 
 Solvent  :  Dimethyl sulfoxide 
WORKING CONDITIONS IN LABORATORY 
 The entire work was done by using horizontal laminar flow hood so as to 
provide aseptic conditions. Before commencement of the work, air sampling was 
carried out using a sterile nutrient agar plate and exposing it to the environment inside 
the hood. After incubation, it was checked for the growth of microorganism and absence 
of growth confirmed aseptic working condition. 
 
INOCULAM STANDARDIZATION 
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 All organisms were grown overnight (24 hours) at 37°C on nutrient agar and 
harvested during the stationary phase. 
 Active cultures for experiments were prepared by transforming a loopful of cells 
from the stock culture to the test tubes containing Mueller Hinton broth, 
incubated for 24 hours at 37°C. 
 Inoculum was standardized by matching the turbidity of the culture to 0.5 
McFarland standards. The standard was produced by mixing 0.05 ml of 1% 
BaCl2 with 9.95 ml of 1% H2SO4 
[122]. 
 If the turbidity of the culture matches that of the McFarland standard, the culture 
inoculating suspension has approximately 1.5×108CFU/ml of bacteria. 
 
ANTI- BACTERIAL SCREENING BY KIRBY-BAUER METHOD [123] 
Mueller Hinton agar plates were prepared aseptically to get a thickness of  
5-6mm. The plates were allowed to solidify and inverted to prevent condensate falling 
on the agar surface. The plates were dried at 37°C before inoculation. The organisms 
were inoculated as per the following method in the plates prepared earlier: 
 The sterile swab was dipped in the previously standardized inoculum and excess 
of inoculums was removed by pressing and rotating the swab firmly against the 
sides of the culture tube above the level of liquid. 
 The swab was streaked all over the surface of the medium three times, rotating 
the plates through an angle of 60°C after each application. 
 Finally the swab was pressed round the edges of the agar surface. 
 The inoculation medium was allowed to dry at room temperature, with the lid 
closed. 
The drug was poured in the wells, which are made with the help of a borer. And 
the measured quantity of the drug is poured with the help of the micro-pipette. Nearly  
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50µl of the solution is poured into the wells. The plates were kept in the refrigerator for 
1 hour to facilitate the diffusion of the drugs. Plates were prepared in triplicate and they 
were then incubated for 18-24 hours at 37°C. After the incubation, the diameter of the 
zone of inhibition around the drugs were measured and compared with that of the 
standard. All the synthesized compounds were tested for antibacterial activity against 
Gram positive and Gram negative bacteria. Saturated solutions of the compounds were 
first studied and the compounds with zones of inhibition greater than 15mm were taken 
for quantitative studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
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 The zone of inhibition of eighteen synthesized compounds is shown in the Fig. 
46 and 47 and their diameters were compared with that of the standard ciprofloxacin in 
Table 7 and 8. 
Table 7: Antibacterial Screening of test compounds against  
Gram positive bacteria 
Sl.No. 
Compound 
code 
Diameter of Zone of 
Inhibition (mm) 
Report 
Staphylococcus 
aureus 
NCIM 2079 
Bacillus 
subtilis 
NCIM 
2063 
Staphylococcus 
aureus 
NCIM 2079 
Bacillus 
subtilis 
NCIM 
2063 
1 N1 13 11 
Moderately  
Sensitive 
Resistant 
2 N2 11 11 Resistant Resistant 
3 N3 11 10 Resistant Resistant 
4 N4 16 12 
Moderately  
Sensitive 
Moderately  
Sensitive 
5 N5 14 11 
Moderately  
Sensitive 
Resistant 
6 N6 11 13 Resistant 
Moderately  
Sensitive 
7 P1 13 11 
Moderately  
Sensitive 
Resistant 
8 P2 14 11 
Moderately  
Sensitive 
Resistant 
9 P3 11 11 Resistant Resistant 
10 P4 14 11 
Moderately  
Sensitive 
Resistant 
11 P5 14 12 
Moderately  
Sensitive 
Moderately  
Sensitive 
12 P6 14 12 
Moderately  
Sensitive 
Moderately  
Sensitive 
13 
Std. 
Ciprofloxacin 
26 27 Sensitive Sensitive 
 
Figure 45: Zone of Inhibition of N1-6 and P1-6 against Gram positive bacteria 
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Zone of inhibition against Staphylococcus aureus NCIM 2079 
  
Zone of inhibition against Bacillus subtilis NCIM 2063 
 
 
 
 
 
 
Table 8: Antibacterial Screening of test compounds against  
Gram negative bacteria 
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Sl. 
No. 
Compound 
code 
Diameter of Zone of 
Inhibition (mm) 
Report 
Escherichia 
coli 
NCIM 2911 
Pseudomonas 
aeruginosa 
NCIM 2036 
Escherichia 
coli 
NCIM 2911 
Pseudomonas 
aeruginosa 
NCIM 2036 
1 N1 15 12 
Moderately  
Sensitive 
Moderately  
Sensitive 
2 N2 11 11 Resistant Resistant 
3 N3 13 10 
Moderately  
Sensitive 
Resistant 
4 N4 15 14 
Moderately  
Sensitive 
Moderately  
Sensitive 
5 N5 13 13 
Moderately  
Sensitive 
Moderately  
Sensitive 
6 N6 11 10 Resistant Resistant 
7 P1 14 14 
Moderately  
Sensitive 
Moderately  
Sensitive 
8 P2 16 17 
Moderately  
Sensitive 
Moderately  
Sensitive 
9 P3 11 12 Resistant 
Moderately  
Sensitive 
10 P4 14 14 
Moderately  
Sensitive 
Moderately  
Sensitive 
11 P5 14 17 
Moderately  
Sensitive 
Moderately  
Sensitive 
12 P6 15 14 
Moderately  
Sensitive 
Moderately  
Sensitive 
13 
Std. 
Ciprofloxacin 
32 29 Sensitive Sensitive 
Sensitive: Diameter of zone of inhibition ≥ 18mm 
Moderately sensitive: Diameter of zone of inhibition 12 to 18mm 
Resistant: Diameter of zone of inhibition < 12 
Figure 46: Zone of Inhibition of N1-6 and P1-6 against Gram negative bacteria 
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Zone of inhibition against Escherichia coli NCIM 2911 
     
Zone of inhibition against Pseudomonas aeruginosa NCIM 2036 
 
 
 
 
 
ANTIMYCOBACTERIAL STUDIES [124] 
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 Conventional agar diffusion technique for susceptibility tests, which rely on the 
size of zone of inhibition surrounding a drug containing disc are not suitable for the 
slowly growing Mycobacterium species because the drug diffuses throughout the 
medium before the organism has the chance to grow. So, the following principles are 
recognized for the antimycobacterial screening. 
 The composition of medium should have a minimal effect on drug inactivation. 
 So, Middle Brook 7H9 broth base is used.  
 Drug containing medium should be stored in a refrigerator shielded from light 
 and kept in plastic tubes tightly closed in order to protect them from 
 evaporation. 
 Homogenization of inoculum is essential to eliminate large clumps of cells. 
 
SUSCEPTIBILITY TESTING 
 This is done by two methods: 
 Direct method 
 Indirect method 
Direct method 
 This was done if acid-fast bacilli are seen on the smear of the concentrated 
clinical specimen. Dilutions are made and inoculated. 
Indirect method 
 In this method, bacterial mass is suspended in Middle Brook 7H9 broth 
containing these or four small sterile glass beads. Mixture is placed on a vortex mixer 
and precautions are taken to prevent aerosol production. Tube is allowed to stand for 
15 min. The stock suspensions are diluted and 0.1 ml is inoculated into control and drug 
containing media. 
 The antimycobacterial screening was carried out in Maratha Mandal NGH 
Institute of Dental Sciences and Research Center, Belgaum. 
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ANTITUBERCULAR SCREENING BY MICROPLATE ALAMAR BLUE 
ASSAY (MABA) 
 Alamar Blue is a cell viability assay reagent which contains the cell permeable, 
non-toxic and weakly fluorescent blue indicator dye called resazurin. It is an oxidation-
reduction indicator used for the screening of cell growth, particularly in various cell 
toxicity studies. The dye changes its colour from blue to pink and becomes fluorescent, 
when reduced to resorufin by oxidoreductases within viable cells. 
N
ONaO O
O
+ N
ONaO O
Resazurin (oxidized) Resorufin (reduced)  
 Alamar Blue is used for the screening of antitubercular activity. Since 
Mycobacterium is an aerobic organism, its presence of growth turns Alamar Blue to 
pink colour. Hence, pink colour indicates the presence of growth (no antitubercular 
activity) and blue colour indicates the absence of growth (inhibitory activity of agents 
tested). 
Procedure [125] 
1) The antimycobacterial activity of compounds were assessed against M. 
 tuberculosis using Microplate Alamar Blue Assay (MABA). 
2) This methodology is non-toxic, uses a thermally stable reagent and shows good 
 correlation with proportional and BACTEC radiometric method. 
3) To the outer perimeter of sterile 96 wells plates, 200µl of sterile deionized water 
 was added to minimize evaporation of medium in the test wells during 
 incubation. 
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4) The 96 wells plates received 100 µl of the Middlebrook 7H9 broth (inoculated 
with Mycobacterium tuberculosis of H37RV Strain) and serial dilution of 
compounds were made directly on plate. 
5) The final drug concentrations tested were 100 to 0.2 µg/ml. 
6) Plates were covered and sealed with parafilm and incubated at 37ºC for five 
 days. 
7) After this time, 25µl of freshly prepared 1:1 mixture of Alamar Blue reagent 
 and 10% tween 80 was added to the plate and incubated for 24 hrs.  
8) A blue color in the well was interpreted as no bacterial growth, and pink color 
 was scored as growth.  
9) The MIC was defined as the lowest drug concentration which prevented the 
 color change from blue to pink.  
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RESULTS AND DISCUSSION 
 The synthesized compounds were evaluated for in-vitro antimycobacterial 
activity by Alamar Blue assay method and the results are shown in table 9. 
Table 9: Antimycobacterial activity of N1-6 and P1-6 
Sl. 
No. 
Samples 
100 
µg/ml 
50 
µg/ml 
25 
µg/ml 
12.5 
µg/ml 
6.25 
µg/ml 
3.12 
µg/ml 
1.6 
µg/ml 
0.8 
µg/ml 
1 N1 S S S S S R R R 
2 N2 S S S S S S R R 
3 N3 S S S S R R R R 
4 N4 S S S S S R R R 
5 N5 S S S S R R R R 
6 N6 S S S S S S R R 
7 P1 S S S S S R R R 
8 P2 S S S S S R R R 
9 P3 S S S S S S S R 
10 P4 S S S S S S R R 
11 P5 S S S S S R R R 
12 P6 S S S S S S S R 
13 
Pyrazinamide 
(standard) 
S S S S S S R R 
14 
Streptomycin 
(standard) 
S S S S S R R R 
15 
Ciprofloxacin 
(standard) 
S S S S S S R R 
 
S- Sensitive 
R- Resistant 
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Figure 47: Antimycobacterial screening of N1-6 and P1-6 using  
Alamar Blue Assay method 
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SUMMARY AND CONCLUSION 
SUMMARY 
 The present work was focused on the designing of novel azetidin-2-one 
derivatives with coumarin moiety having antitubercular activity. For this, 
following approach has been adopted. 
PHASE I: DRUG DESIGN APPROACH 
 It involves the following stages: 
Stage 1: Identification of target 
 Cytochrome P450 lanosterol 14α-demethylase in Mycobacterium 
tuberculosis (MT-CYP51) was selected as the target enzyme as its inhibition will 
prevent synthesis of the membrane lipids. This compromises membrane integrity 
and induces Mycobacterial cell lysis. 
Stage 2: Lead Identification 
 The lead coumarin was selected based on several literature reviews. 150 
compounds including a series of azetidinone, imidazolidinone, thiazolidinone and 
oxazolidinone derivatives of coumarin were subjected to molecular docking 
studies. All the compounds were found to have binding energy lesser than that of 
the standard fluconazole. A series of twelve azetidinone (az31-az42) derivatives 
were selected from these compounds on the basis of their binding energy. az37 
(P1) and az38 (P2) was found to have the least binding energy of -11.28 and -
11.24, respectively. 
 
Stage 3: Lead optimization 
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 Safety and efficacy of the lead molecules were evaluated by observing the 
in silico ADME studies and computation of drug like properties. Twelve ligands 
(N1-6 and P1-6) were subjected to in silico lead optimization. Oral bioavailability 
was evaluated was evaluated by using Molinspiration server and ADMET data 
were obtained from Accelry’s Accord for Excel. All the compounds possessed 
good bioavailability and permeability.  
PHASE II: SYNTHESIS AND PHYSICAL CHARACTERIZATION 
A) Synthesis of the designed compounds 
In this work, twelve new compounds were synthesized. The first step 
involved the synthesis of 4-hydroxy-3-formyl coumarin by Vilsmeier-Haack 
Reaction. Schiff bases were prepared from these aldehydes using various primary 
amino compounds. Finally, the Schiff bases were cyclized to form azetidin-2-
ones. 
 
B) Physical characterization 
 Melting point and Rf  values of all the synthesized compounds were found 
out. 
PHASE III: SPECTRAL STUDIES 
 The structures of the synthesized compounds were established on the basis 
of UV, IR, 1H NMR and MASS spectral data. 
 
PHASE IV: EVALUATION OF BIOLOGICAL ACTIVITIES 
A) Antimycobacterial activity 
 Antitubercular screening of the synthesized compounds were done by 
Alamar Blue assay method in Middlebrook 7H9 broth against Mycobacterium 
tuberculosis H37RV strain (ATCC No. 27294).  All newly synthesized 
compounds N1-6 and P1-6 showed antimycobacterial activity by inhibiting the 
growth at concentration of 12.5µg/ml. In the chlorine substituted series of 
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azetidinones, N2 (nicotinamide) and N6 (nicotinic hydrazide) showed minimum 
inhibition at a concentration of 3.12µg/ml. N1 (isoniazid) and N4 (4-amino 
pyridine) showed minimum inhibition at 6.25µg/ml. In the series of  phenyl 
substituted azetidinones, P3 (2-amino pyridine) and P6 (nicotinic hydrazide) had 
shown promising activity with MIC of 1.6µg/ml. P4 showed MIC at 3.12µg/ml. 
 
B) Antibacterial activity 
 The synthesized compounds were screened for antibacterial activity 
against both gram positive (Staphylococcus aureus NCIM 2079 and Bacillus 
subtilis NCIM 2063) and gram negative (Escherichia coli NCIM 2911 and 
Pseudomonas aeruginosa NCIM 2036) organisms by Kirby-Bauer method. All 
the compounds were found to be moderately to weakly active against bacteria. 
Comparatively, N4 and N6 were found to have better activity against Gram 
positive bacteria. N1, N2, N6, P2, P5 and P6 were found to have better activity 
against Gram negative bacteria. 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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 The present study establishes that computational tools help in minimizing 
the tedious process of drug discovery and delivers new drug candidate 
more quickly. 
  Cytochrome P450 lanosterol 14α-demethylase in Mycobacterium 
tuberculosis (MT-CYP51) was selected as the target and coumarin as the 
lead, which was optimized based on drug likeness score. 
 The proposed twelve compounds were synthesized and their structures 
were established based on spectral data. The compounds were evaluated 
for antibacterial and antimycobacterial activity. 
 The synthesized compounds showed poor to moderate antibacterial 
activity. 
 Five synthesized derivatives (N2, N6, P3, P4 and P6) showed equipotent 
antitubercular activity compared to the standards Pyrazinamide and 
Ciprofloxacin at concentration of 3.12µg/ml. Two synthesized derivatives 
(P3 and P6) exhibited higher level of antitubercular activity even at a low 
concentration of 1.6µg/ml. 
 Among the synthesized compounds, 3-phenyl substituted azetidin-2-ones 
showed promising antimycobacterial activity. 
 Among the synthesized compounds, P3 and P6 can be taken as the lead 
molecule and acute toxicity studies are to be done on these promising 
compounds.  
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LIST OF NEWLY SYNTHESIZED COMPOUNDS 
CHLORINE SUBSTITUTED AZETIDINONE DERIVATIVES 
O
OH
N
R
Cl
O
O  
Compound 
code 
R Compound name 
N1 
N
NH
O
 
3-chloro-4-(4-hydroxy-2-oxo-2H-chromen-3-
yl)-1-(pyridine-4-carboxamido)azetidin-2-one 
 
N2 
N
O
 
3-chloro-4-(4-hydroxy-2-oxo-2H-chromen-3-
yl)-1-(pyridin-3-ylcarbonyl)azetidin-2-one 
 
N3 
N
 
3-chloro-4-(4-hydroxy-2-oxo-2H-chromen-3-
yl)-1-(pyridin-2-yl)azetidin-2-one 
N4 
N
 
 
3-chloro-4-(4-hydroxy-2-oxo-2H-chromen-3-
yl)-1-(pyridin-4-yl)azetidin-2-one 
N5 
N
N
 
3-chloro-4-(4-hydroxy-2-oxo-2H-chromen-3-
yl)-1-(pyrimidin-2-yl)azetidin-2-one 
N6 
N
NH
O
 
3-chloro-4-(4-hydroxy-2-oxo-2H-chromen-3-
yl)-1-(pyridine-3-carboxamido)azetidin-2-one 
PHENYL  SUBSTITUTED AZETIDINONE DERIVATIVES 
List of Newly Synthesized Compounds 
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O
OH
O
N
Ph
R
O
 
Compound 
code 
R Compound name 
P1 
N
NH
O
 
4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-
phenyl-1-(pyridine-4-carboxamido)azetidin-
2-one 
P2 
N
O
 
4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-
phenyl-1-(pyridin-3-ylcarbonyl)azetidin-2-
one 
P3 
N
 
4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-
phenyl-1-(pyridin-2-yl)azetidin-2-one 
 
P4 
N
 
4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-
phenyl-1-(pyridin-4-yl)azetidin-2-one 
P5 
N
N
 
4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-
phenyl-1-(pyrimidin-2-yl)azetidin-2-one 
P6 
N
NH
O
 
4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-3-
phenyl-1-(pyridine-3-carboxamido)azetidin-
2-one 
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